CA2147825A1 - High purity beta-carotene - Google Patents
High purity beta-caroteneInfo
- Publication number
- CA2147825A1 CA2147825A1 CA002147825A CA2147825A CA2147825A1 CA 2147825 A1 CA2147825 A1 CA 2147825A1 CA 002147825 A CA002147825 A CA 002147825A CA 2147825 A CA2147825 A CA 2147825A CA 2147825 A1 CA2147825 A1 CA 2147825A1
- Authority
- CA
- Canada
- Prior art keywords
- carotene
- beta
- cis
- solvent
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Compositions of high-purity natural beta-carotene and of the 9-cis isomer of beta-carotene are provided, as are methods for the production of these compositions from plant matter, conveniently algae such as Dunaliella species. Typically, the compositions contain at least about 50 % 9-cis beta-carotene and less than or equal to 40 % of all-trans-beta-carotene, and in some cases may contain 75 % 9-cis beta-carotene or higher. The compositions are suitable for administration to humans or other animals, particularly for oral delivery, in a variety of formulations and dosages as pharmaceutical agents or as dietary supplements.
Description
~,i .. ~ 1 ;`
1 4 7 ~
~VO 94~10140 PCr~US93/jlO31~
I
HI&H PURITY BETA-CAROTENE
S
Backqround of the Invention The present in~reIltion relates ~enerally to ::ompositions of puri~ied na~ural beta-carotenes and methods for their puri~ication from plants.~ More particularly, the beta-carotene preparations are enric:hed in the ~ is isomer compared to the all~trans isomer. The purified beta~carotenes are useful as dietary vitamin A supple~nentation, as phaxmaceuticals and ~ particu}arly preparations containing high purity ~-cis beta-carotene, as anti-oxidants in a ~ariety o~
therapeutic and preventative application~.
The carotenes are che~ical precursors of Yitamin A~
Vitamin Al, which is synthesized frbm carotenç~s, is essential to a wide variety of physiologic processeC in an~mals, inaluding humans. For example, vita~in A is important in visual sen~itivity, and deficienci2s of ~ vitamin A ~ay lead~ to lack of night ~ision or e~en ~lindness~ Vit:amin A is aIso ne~t:essary to the proper functioning of epithelial tissues.
The carotenes are co~po ed ~f several fo~s, including alpha-, beta~ and gam~a-carotenes. 0~ these, the b~ta carotene isomers have the ~ost ~ita~in A acti~rity and are ', the most prevalen~ in nature, beinq ~ound in dark green leafy v~getab!les, yellow and oranS~e ve~etables and fruits, and in a1gae. The concentration of beta~carotene in the edible plants is r~latiYely low and large ~uantities ~aus~ be ~; consum2d, or else the beta carotene; must be supplied as a t.
d i etary suppl ement .
: , ~ore recently,: beta-carotene has~been repor~:ed to ~.
3 5 pre~rent o~ reduce the risk o~ heart disPase and s~roke and certain ty2es o:f cancers j such as cancer of the breas.r lung, ~: colGn, ~pros~ate,~- and cer~rlx.
: :
W094/10140 PCT/US93/1jO314 --To meet the growing commercial marke~s in health and coloring industries, a number of methods have been proposed to purify the beta-carotenes. Few proceduxes, i~ any, h~wever, have successfully overcome ~he considerable o~stacles posed by the ~eed to prepare compounds o~ high purity from natural sources in an economical manner while maintaining acceptability to the cons~mer and regulatory agencies. For example, U.S~ Patent No. 4,439,629 to Riiegg describes treating algae wi~h calcium hydroxide at an elevated temperature to saponi~y the chlorophyll and produce a residue which is then ~iltered, dried, and extracted wi~h a 501~ent, such as a halogenated hydrocarbon or an aliphatic or aromatic hydrocarbon, and recrystallized to yield enriched all-trans beta carotene.
~5 U.S Patent No. 5,019,~68 ~o ~eat et al., describes the recovery of carotenoids fro~ palm oil by an esterification process using an edi~le ~il a~d s~j ecting t~e ~ixture to ~ acu~m distillation at a substantially eleYated temperature.
The concentration o~ beta-carotene in the~e preparations w~s 2 0 described as being up to about 1. 9 9c .
U.S. Patent No. 4,680t314 to Nomura et al.
describes a process for concentrating algae and extxacting be~a-carot2ne with an edible oil such as vegetable oil at elevated temperatures, i . e., 66 -100 C. The concentration of car~tene in the oil extract was reported to be on the order of 1., 99c . U. S . Patent No . 4, 713, 398, also to NoD~ura et al ., descri~es compositions o~ carotene prepar~d ~ro~ algae at concentrations of 0. 5~ to 7 . 5~ by weigh~ of an edihle-oil ~ I mediti~
1 4 7 ~
~VO 94~10140 PCr~US93/jlO31~
I
HI&H PURITY BETA-CAROTENE
S
Backqround of the Invention The present in~reIltion relates ~enerally to ::ompositions of puri~ied na~ural beta-carotenes and methods for their puri~ication from plants.~ More particularly, the beta-carotene preparations are enric:hed in the ~ is isomer compared to the all~trans isomer. The purified beta~carotenes are useful as dietary vitamin A supple~nentation, as phaxmaceuticals and ~ particu}arly preparations containing high purity ~-cis beta-carotene, as anti-oxidants in a ~ariety o~
therapeutic and preventative application~.
The carotenes are che~ical precursors of Yitamin A~
Vitamin Al, which is synthesized frbm carotenç~s, is essential to a wide variety of physiologic processeC in an~mals, inaluding humans. For example, vita~in A is important in visual sen~itivity, and deficienci2s of ~ vitamin A ~ay lead~ to lack of night ~ision or e~en ~lindness~ Vit:amin A is aIso ne~t:essary to the proper functioning of epithelial tissues.
The carotenes are co~po ed ~f several fo~s, including alpha-, beta~ and gam~a-carotenes. 0~ these, the b~ta carotene isomers have the ~ost ~ita~in A acti~rity and are ', the most prevalen~ in nature, beinq ~ound in dark green leafy v~getab!les, yellow and oranS~e ve~etables and fruits, and in a1gae. The concentration of beta~carotene in the edible plants is r~latiYely low and large ~uantities ~aus~ be ~; consum2d, or else the beta carotene; must be supplied as a t.
d i etary suppl ement .
: , ~ore recently,: beta-carotene has~been repor~:ed to ~.
3 5 pre~rent o~ reduce the risk o~ heart disPase and s~roke and certain ty2es o:f cancers j such as cancer of the breas.r lung, ~: colGn, ~pros~ate,~- and cer~rlx.
: :
W094/10140 PCT/US93/1jO314 --To meet the growing commercial marke~s in health and coloring industries, a number of methods have been proposed to purify the beta-carotenes. Few proceduxes, i~ any, h~wever, have successfully overcome ~he considerable o~stacles posed by the ~eed to prepare compounds o~ high purity from natural sources in an economical manner while maintaining acceptability to the cons~mer and regulatory agencies. For example, U.S~ Patent No. 4,439,629 to Riiegg describes treating algae wi~h calcium hydroxide at an elevated temperature to saponi~y the chlorophyll and produce a residue which is then ~iltered, dried, and extracted wi~h a 501~ent, such as a halogenated hydrocarbon or an aliphatic or aromatic hydrocarbon, and recrystallized to yield enriched all-trans beta carotene.
~5 U.S Patent No. 5,019,~68 ~o ~eat et al., describes the recovery of carotenoids fro~ palm oil by an esterification process using an edi~le ~il a~d s~j ecting t~e ~ixture to ~ acu~m distillation at a substantially eleYated temperature.
The concentration o~ beta-carotene in the~e preparations w~s 2 0 described as being up to about 1. 9 9c .
U.S. Patent No. 4,680t314 to Nomura et al.
describes a process for concentrating algae and extxacting be~a-carot2ne with an edible oil such as vegetable oil at elevated temperatures, i . e., 66 -100 C. The concentration of car~tene in the oil extract was reported to be on the order of 1., 99c . U. S . Patent No . 4, 713, 398, also to NoD~ura et al ., descri~es compositions o~ carotene prepar~d ~ro~ algae at concentrations of 0. 5~ to 7 . 5~ by weigh~ of an edihle-oil ~ I mediti~
3 o Beta-caro~er~e has been prepared by chemical synthesis:, ~ut results in ~he production of only 'ch~ all-trans ~;
~orm and very little of the cis-is~mers of beta-carotene.
There remains a si~nifican~ need in the art for a method of producinq natural beta-carotene compositions of high s : purity, par~icularly co~positions ~hich are erlriched in the 9-::is iso~er of beta carotene. The method desirably will p~ovide betaocarotene in a for~ which maintains its anti~
' 4 7 ,~ 2 5 WO94/10~40 PCT/US93~103]4 oxidant capa~ility, and in a form which is acceptable to food and health regulatory agencies and to consumers. Moreover, the methods should provide the ability to produce the beta-carotene containing compositions on a large ~cale and in an ~:
economically feasible manner. Quite surprisingly, the present invention fulfills ~hese and other related needs.
~D_ The present invention provide~ compositions of natural high~purity beta-carotene and of the 9-cis isomer of beta carotene, and methods for their Rroduction from plant matter. Thus, in one e~odiment the in~ention comprises substantially puri~ied, naturally-occurring beta-carotene isomers, in relati~e amounts of at 122~t 40% 9-ci~ beta-carotene and less than abo~t 50% all-trans be~a-carotene, more typically comprising at least about 50S 9-cis beta-caxotene and less than ar equal to 40~ o~ all-trans-~2ta-carotene. The amount of alpha-carotene in these preparations ~sually is less tharl about 109~ of the total amount of carotene present. As the preparations are derived fro~ a natural sQurce, con~niently algae such as Dunaliella species, the compositions may f~rther comprise other:carotenoids (generally : about 2% ar less) and o~her cis-~eta carotene isamers (generally about 3~ or less). The compositio~s are s~stantially free o~ organic solvent and thus are suitable ; . ~or administration to hu~ans or other ani~als. I .
In other embodiments the compositions, including ~-pharmaceu~ical compositions, proYided by the invention comp~ise at leas~ about 60% 9-cis ~eta-carote~e a~d less than js or equal to 25~ all-trans beta-caro~ene, and in some cases the ~,.
be~a-carotene may be 75S g-cis beta-carotene or higher.
I 35 F~rmulations o~ high purity 9-cis be~a-carotene are j particularly useful for oral delivery.
WO 94/10t40 ~ 7 ~ ~ PCr/US93/10314 ~ ' The high purity natural beta-caro~ene preparations may be combined with pharmaceutic::ally acceptable carriers, prese~ratives, vitamin supplements or other medicinal~ agents in a variety of formulatic:ns and dosages for administration to humans or other znimals, such as livestock, as ph~rmaceutical agerlts or as dietary supplements. The formulation ar~
typically a capsule, liquid, tablet or powder.
In yet other aspects the inYention provides convenient and economical methods for purifying beta-carotene, including the g-cis isomer of beta-carotene, from plants.
Plant material, such as algae, is extracted with a solvent or mixture of solYents, typically an organic solvent such as hexane, petroleu~ ether~ cyclohexane, ethyl acetate, e~hanol, etc. to produce a crude mixture of car~tenes. The sol~ent is removed ~rom the extr~ct znd the extract is then r~dissolved in a non-polar solvent such as hexane, petroleum eth~r, cyclohexane, etc. and chro~at~graphe~ on a column o~
deacti~ated alu~ina. Fractions containing ~he purified beta-carotene are then collected fro~ the colu~n.
2 0 To produce high-purity 9-cis 1 somer of beta carotene, in one me~od t~e high-purity natural beta- ::aro~ene ::ollected from the colu~n is flsrther proc~ssed. Typically the puri~ied ~eta-carotene is dissolved in a non-polar sol~ren~ at about 35-55 C to for~ a sattlrated solution, which is then chilled to crystallize out the all-~rans beta~caxotene portic: n . The solvent is ~hen remoYed froIQ the supernatant sol~ti~n to yi~ld a preparation substantially enriched an 9- j cis beta-carot*ne. The procedure may be repeated, i.e~, the ??
step~ of dissolving in warm rlon-pol2r solvent, chilling to '.
crystallize the all-trans b~ta-CarQtene~ separ~ting the ?r solution fr~m the crystals ~ and removing the solven~ to yield a preparation further enriched in 9 cis beta ::arotene.
.
l~ ~
WO 94/l0140 .~ 1 ~ 7 S 2 ~ PCI/US93/10314 t` `
Brief PescriPtion o~ th~ p~ çs ` !~
Fig. 1 is a chromatogram depicting highly enriched 1-natural ~eta-carotene a f ter initlal fractionation . ¦.
Fig. 2~ is a chromatogram which shows the same material as in Fig. 1, but with the ,B-caro~ene isomers resolved by use of a Vydac column. ~igs. 2B and 2C ~re a c:hromatograms from su~sequent purification steps to produce preparations enriched for the 9-cis isomer and all-t~ans isomer, respectively, of beta-carotene.
i ,~ Des~ri~on of_the SDeC ' ~iO Embodiments ;~ 15 The present invention provid~s methods for the preparation of~ highly purified natlaral beta-caro~ene and compositions con~aining the hi~h purity natural be~ carotene.
The methc~ds generally: involve the separatlon of the beta- :
carotene fro~ the neutral and polar lipids of the crude pla2lt extract and removal o f o~qen-c:ontaining carotenoids.
Alsc) provid~d are D~etho~ls ~or the preparation of and con~posi~ions of nat~ral high purity 9-Ci5 isomer of beta c:aro~ene. The compositions may be for~ulated and used in a num~er of ways, including, among oth~rs, as dietary suppl~ments for hu~ans and other animals, and in the pre~ention and treatment o~ certain neoplastic c:onditions. ~-The beta carotene containing composi~ions of the ' invention ~ay be prepar d froD~ a Yariety o~ plan~ ma~erials, s~lch as algae, palms, veget~bles such as spinach, broccoli, alfalfa, and other plants. This method may also be used to p-lrify ~Ea~ is~er froDl carrots and sweet potatoes, e~c.
. Prefera~ly the plants are algae. Among the algae, preferred . classes are Chlorophyta (green algae), of which the preferrec~
genus is Dunaliella. Ot:her genera may be used so long as c:arotene can be produc~d in relatively large ~uan~ities.
~ `'i,~`, WO94/tO140 i~1 4 ~ ~ 2 S PCT/US93110314 Cultivation techniques may ~ignificantly incxease the amount .
of carotene present in each algal cell.
Typically, the algae are raised in shallow tanks, bioreactors, man~made or natural ponds at a wide range of s temperat~res, e.g~, from 15-~O~C, more preferably about 25-45C. Preferably the c~lture medium is salt water, but fresh water can also be used. Fresh w~ter may be made salin.o by the addition of salt a~ a culture medilL~. The medium ma~ be supplemented by the addition of nitrate, pho~phate, bicarbonate, iron and trace minerals. ~rotocols for the large scale propagatian of algae are described in, ~or example, A.
Richmond, andbook of-Microalqal M~ss ~ul~l~, CRC Press, Boca Raton, Fl., (1986), which is incorporated herein by reference.
When the algal culture reaches the desired density , e . g ., a~out û.25 to 0.5 grams dry weightJlite~, as determined ~y absorba~ce, the algae are har~rested from the tank or pond by pumping out the wat~r slurry contain~ the dispersed alyae.
T~e slurry may be passed throu~h screens which are su~ficiently coarse to allow algae through but which remo~re lar~er unwanted obj ects .
The slurry is then concentrated in algal content, typic:ally by evaporation, centrifugatiorl, flocculation, ultrafiltration, flotation, etc~ to allow re~oval o~
unnecessary water. In one embodi~ent, following concen~ration o~ the slu ~ the salt is largely re~oved by addition of fresh h~t water and u~tra~iltration. This also breaks the algal cells, libera~ing ~he beta-carotene. The concPntrate is then centxifuged in a suitable continuous flow centrifuge, such as a cream separator, to yield ~n upp~r (crea~) phase of carot ne and lipid, which is continually re~oved. This is dissol~ed in : a suitabl~ solvent, such as hexane, cyclohexane, petroleum ether, etc. as descri~ed below.
In another embodi~ent, the algal material is dewatered by centrifu~ation, ultrafiltration, etc., and the carotenes are then extracted fro~ the algal or other plant preparation by use of a suitable organic solvent. The extraction and subseouent purification procPdures are W094/lOt~O 2 1 ~ 7 2 ~ 3 PCT/US93/1~314 j~
typically performed under low light intensity and under vacuum or an atmosphere of inert gas (e~g., nitrogen) to maxi~ize recovery of non-oxidized carot2nes. The extraction~solvent or solvent mixture may be organic, ~uch as hexane, hexanes, ¦`
pentane, heptane, octane, petroleum ethers, cyclohexane, ethyl acetate, acetone, or ethyl alcohol, or inorganlc, ~uch as, for example, carbon dioxide as a liquid or as a super-critical ~luid.
The solvent is then removed from the crude extract, typical}y by eqraporating under vacuum, and ~he crude extract is dissolved in ~ minimum amount o~ a suitable non-polar solvent, such as hexane, petroleum ether~, cyclohexane, etc.
The solution of extracted and re-dissolved carotene is then applied to a chromatographic colu~n of alumina, preferably alumina which has been deactivated (partia~ly or totally), or silicic acid, FLORISI~9 (magnesiu~ sllicate) or the like. The alumina is deacti~ated by suspending it in aqueous ethanol (ethyl alcohol:water at 7Q:30 v/~) or si~ilar procedura. Ihe alumina is then packed into the column as a 1~0 water/alcohol slurry~ The colu~n is typically washed to remove the water, s~ch as with ethanol, then wit~an ethan~l/hexane mixture, e.g., 40S ethanol:60~ hexane. Several column volumes o~ a suitable non-polar solvent, e.g., hexane, petrol~um ethers, etc. followed by additional washes;
typically at least about five to six column ~olu~es, o~ a 100%
non-polar solvent, such as hexane, pentane, heptane r octane, petroleum ethers, e~c., but preferably hexane, to completely remove any remaining ethaAol from the columnO
The resolubili~ed carotene'extract is then applied to th~ column. The extract is washed throu~h the column, typically using the same non-polar solvent as that in which it is dissolved, preferably hexane. Fractions containiny t~e m~in band of orange-red car~tene are then collected and the salvent removed,:typically by eYaporation and preferably in ~ ~35 vacuo. The fraction then con~alns the high purity na~ral : : beta-carotene. By "high purity ha~ural beta-caro~ene" as used ~: herein is meant a composition which comprises fro~ 30-60% all-I ~
~: .
W094J10140 21A~ 8æs PCl/USg3~10314 '- ' trans-beta-carotene, 40-70% 9-c~s-beta-carotene, up to a maximum of about 10% alpha-carot~ne, and up to no more than , about 6~ of other mono-cis and dl-cis beta-caxot~ne ~somer~ ~ , j combined. A typical preparation of high purity na~ural beta- !
1 5 carotene of the invention comp~i6es 50S 9-cis-beta~arotene, 40% all-trans-beta-carotene, 5~ alpha carotene, 2% other 1 carotenoids, and 3% other cis-~eta-carotene isome.rs.
3 After elution of the beta-carotene fraction from the column, elution with the same solvent i5 continued a~d subsequent fractions immedia~ely following the main color band are collected, with another four to five column volu~es being I collected to remove virtually all o~ the pale yellow remaining ! caxotenoids, including some beta-carotene. This is useful as I a pro-vitamin supplement or ax a natural coloring agent.
! 15 Periodically ~he column may be cleansed to remove any more polar carotenoids, plant lipids and chloropAyll from the column, typically by bacX-wa5hing wi~h a polar solvent such as acetone and~or ethanol. T~is wash i~ fur~her processed by evaporation to recover solvent. Salids ~ay be discarded or used in animal feed or as a health fo~d. The colu~n is then washed wikh 40S ethanol/non-polar solvent, f~llowed by pure non-polar solYent as described above to r~store it ~or further c~rotene purification~ Periodically the ` build-up of green pigment and a}gal lipids cannot be eluted2S and the column may need to be repacked with fre~h alumina as I described abo~e.
¦ The natural high purity beta carotene preparation ! prepared as ab~ve may be us~d to produco co~positions which ! comprise even.further more highly purified 9 cis isomer beta-~axotene~ By "high purity natural 9-cis beta-carotene" as used herein is meant a mixture of alpha- and beta-carotenes derived fr~m a plan~ source which comprises greater than 60%
9-cis-~eta-c~rotene. Preferably the natural 9-cis-beta- .
,j carotene comprises at lea-~t 70% of the composition, more j 15 preferably at least about 80%, and most preferably 90~ or more. Typically the ratio of ~-cis-beta-carotene to al}-~j 2 1 4 7; ~ ~
WO ~4/10140 PCT~US93/10314 9 ~`.
trans-beta-carotene will be greater than or equal to 3 . O
preferably at le~st abc:ut 5.0~
The high-purity natural 9-cis-~eta-c:aro~erre is produced by dissolving the high purity beta-carotene preparation in the minimal amount of warm (typically 40-50 C) non-polar solvent needed to ~olubilize the beta carotene. A
variety of non-polar solvents may be used, such as, for example, hexane, ~yclohexane, pentane, heptane, octane, petroleum ethers, but preferably hexane. Thi~ solution is chilled, typically to about -20C, to cause the preferential c~ystalli2ation of the all-trans is~er of beta-G2rotene. The crystal5 are then separated from the supernatant solu~ion by any of the usual separation me~hods, e.g,, filtration, centrifugation, decanting, etc. The r~maining supernatant solution is then evaporated to re~o~e ~he sol~ent, leaving a carotene preparation which co~prise. highly p~rified 9-cis-beta-carotene isomer. The final p~eparations will be substantially free o~ the orsanlc solvent. By su~stantially ~ree is meant that t~e preparation will conta~n no or little txace of organic solvent, and in any event will not exceed that amount permitted by regulatory aqencies for.
administration to humans. To remove additional all-trans beta-carotene and produce a more highly puri~ied 9-cis-~eta carotQne preparation, the supernatant solution cont:ainir~g the 9-cis-is~mer can be re-e~raporated " ~e-dissol~ed in a minimal amount of solvent as abo~re, and re-crystalliz~d by chilling.
The resulting all-txans beta carotene by~prod~ct is typlcally 75gc or more pure, and can be used for a variety of purposes, such as~, for `example, a source of vitaaQln AJI a 3 O natural coloring produc:t, or a5 a disease preventati~e or ..
reatment.
The compc~sitions of hiqh-purity natural beta- -carotene and 9-cis beta-carotene find a wide variety of uses, including as pharmaceuticals and as dietary ~ritamin 3 5 supplements .
Dependinq on the intended mode af administ_ ation and the intended use, the compositians may be in the for~ of ~ 5 ~ ~:
~n 94/1~140 PCT/US93~0314 ~"
solid, semi-solid or liquid dosage forms, such, for example, as tablets, capsules, pills, microbeads, beadlets, powders, ~ granules, crystals, liquids, suspensions, liposomes,~etc., j preferably in unit-dosage form~ suitable for administration of relatively precise dosages. The compositions may include a conventional pharmaceutical carrier or excipi nt and, in addition, may include other medicinal agents or vitamins, pharmaceutical agents, carriers, etc.
The high-purity natural beta-carotene and 9-c~s beta-carotene of the invention may be ad~inistered in relatively large amounts without seriQus side effects, althou~h indiscriminate use may produce yellowing of the sXin.
In cases where the compositions are administered to preven~
the emergence of disease in subjec~ susceptible to certain ~ 15 types of neoplasia, cardioYascular disease, etc., ~r to those 9~ suf~ering ~rom only mild or borderline disea~e, the dose may ~e adjusted accordingly to lower ~aintenanc~ levels.
For solid compositions, as would be appropriate for oral ad~inistration, ~he high-purity natural beta-carotene and 2~ ~-cis beta-carotene c~n be provided separately or may be compou~ded with conventional nontoxic solid carriers such as, for example, pharmaceutical grades o~ mannitol, lactose, s~arch, magnesium stearate, tal ~ , cellulose, glucose, sucrose, magnesium carbonate, and the liXe. Such compositions take the form o~ solutions, suspensions, tablets, pills, ~apsules, powders, granules, cry~tals, sustained-release ~ fo~mulations, and the like, and ~ay contain about 10-100~ ~
ac~ive ingredient, prefera~,ly about 25-goS.
. I Liquid:pharmaceutically~administrable co~posi~ions ~ 30 can, for example, be prepared ~y dissolving the hi~h-purity ¦ natural beta-carotene and/or 9-cis beta-carotene and op~ional. ,~
! pharmacautical adjuvan~s in a carrier for suspPndin~ or ¦ dissolvinq, such as, for exa~ple, mineral or vegetable oil and Y~ the like, to thereby form a solution or suspension. The 3 5 concentration ~ f the high-purity natural ~eta-carotene or 9-Z cis ~eta-carotene in 'chese fon~lulations can vary ~idely, and will be selected primarily by intended use, viscosities, et~., ~, .. 1`,`.,.`.
" ```~` 2 .1. 4 7 ~
W094/tOl40 PC~/US9~/~0314 in accordance with the particular mode of administration selected.
As a dietary supplement the high-purity natural beta-carotene or 9-cis beta-carotene may be supplied as an oil, ~suspended in a capsule, ~eadlets, etc. or incorpor~ted directly into foodstuffs as a con~enient means of administration .
If desired, the phar~aceutical composition to be administered may also contain minor amounts of nontoxic auxiliary subs~ances such as anti-oxidants, e.gO, vitamin E
I (tocopherol~, BHA, BHT, pH buffering agents and the like, for ¦ example, sorbitan monolaurate, triethanolamine, sodiu~
! a~etate, triethanolamine oleate, etc. Actual methods of I preparing such dosage ~orms are known, or will be apparent, to ¦ 15 tho5e skilled in this art; for example, see Remington's Pharmaceutical Science, 17th ed., Mac~Pu~lishing Co~pany, Easton, PA (1985~, which is incorporated her~in by re~er~n~e.
The composition or fo~mulation to b~ ad~inistered will, in any èv~nt, con~ain a ~uantity o~ the high-purity natural beta-carotene and/or 9-cis beta carotzne in an amount effective to ~ alleviate or amaliorate the s~mptoms of disease or inhibit : their em~rgence in ~he subject.
. The pur~ied ~eta carotene co~positions of the in~ention may be administered ~cr a variety of therapeutic or 2S prophylactic uses to humans or in~veterinary applications.
The compositions may be used as a vitamin preparation, alone or in conjunction wit~ other ~itamins, to supple~en~ dietary intake of vitamin A and thus to treat or pr~ven~ conditions ~ i ` associated with vita~in A insu~ficiency. As beta-carotene, and particularly 9-cis beta-carotene, are anti-oxidants~which can function in lipid environments at the low partial pr~ssures of o~ygen found in animal and hu~an tissues, the compositions of ~ the inven~ion can also be used in preventîon or treatmen~ of a :~ varieey of diseases or pathologlcal conditions associated with ~:35 free radicals and:lipid auto-oxidation.
In other uses the high-puri~y natural be~a-carotene or 3-cis beta-carotene are a~inistered theraDeutically or :' :
~, ~
i.` ,'~ ~ 4~
~ WO94/10140 PCT/US93/10314 `"! 12 prophylactically for a variety of cancers, particularly epithelial cell cancexs. Beta-carotene preparations have shown significant protection against various tumors in ~c~ animals. Among the animal models of cancer which established i~' 5 a protective or other beneficial effect of bet~-c~rot2ne are sXin cancers, includinq thos~ induced by ultraviolet light (~pstein, ~hotochem. Photobiol. 25: 211 ~1977), and ~athews-.~ Roth, in Current ChemotheraDY_and In~ec~ Diseases, eds.Nelson and Grassi, Amer. Soc. Microbiol., Wash. D.C., p. 1503 , (1980)), breast cancers (Santamaria et al., Med. ~iol~
Environ. 12:533 (1984) ), fibrosarco~as (Combs et al ., utr.
Cancer 12:371 (1989) j, epidermoid ~rcinomas (Shklar et al., ~utr. Cancex 12:321 (1989) ), gastric cancer (Santamaria et ;~ al , J. Nutr. Growth Can~er. 4:175 (1987) ), colon cancer i,.~ 15 (Santamaria et al., Pre~, Med. 18:603 (198g)), exocrine , pancreas neoplasias (Wouterson et al., 53CÇ9~ 42:79 19%8) ), ~ladder cancer (Mathew~-Roth et al., ~D~,~Y 48:177 tl9~1) ), and ~irus induced cancer tSei~ter et al., J. ~Jatl.
.,i~ ~ 78:1211 (19~2)).
ao Accordingly, the beta-caxotene and/or 9-cis beta carotene pr~parations of the invention are indicated for use ;~ in therapeutic methods .~or a variety of cancers, including in .~ humans. Beta-carotene preparations haYe been shown to be useful in treating, inhibiting or o~erwise preventing tu~nors ~2S in humans~ including lung canc~rs, such as s~amQus cell .1 c:arcinoma, cancers of the gastrointestinal trac:t, e.g., mouth (Stich et al~, ;rltl J. Cancer 42:195 (1988) and Stich et.al., ',~ in Carotenoids: C~emistry:_and 8iolo~, eds. ~rins~cy et al., ~,-~3 I Plenum Press, p. ~13 (19'~0) ~, pharynx, larynx (Plac3cerras e~
0 al., Amer. J E~idemi ol. 123: 980 (1988) ), esophagus, stomac:h 4:
Graham et al., ~a~5~n~ 13: 19 ~1990)), colon (Santamaria et al., ~ 13: 603 (1989~, Te~Dple et al., J. Natl .
can~e~ s~: 78 :1211 (1987) and Graham et al., ~, . Natl . canc:e-Inst~ 61:709 (1978) ), rectum, bladder (Comstoc3c et al., Amer.
.~5 J. Clin. Nut-. 53 :260s (1991~, Tyler et al., Eur. J._Sur~. :
~orm and very little of the cis-is~mers of beta-carotene.
There remains a si~nifican~ need in the art for a method of producinq natural beta-carotene compositions of high s : purity, par~icularly co~positions ~hich are erlriched in the 9-::is iso~er of beta carotene. The method desirably will p~ovide betaocarotene in a for~ which maintains its anti~
' 4 7 ,~ 2 5 WO94/10~40 PCT/US93~103]4 oxidant capa~ility, and in a form which is acceptable to food and health regulatory agencies and to consumers. Moreover, the methods should provide the ability to produce the beta-carotene containing compositions on a large ~cale and in an ~:
economically feasible manner. Quite surprisingly, the present invention fulfills ~hese and other related needs.
~D_ The present invention provide~ compositions of natural high~purity beta-carotene and of the 9-cis isomer of beta carotene, and methods for their Rroduction from plant matter. Thus, in one e~odiment the in~ention comprises substantially puri~ied, naturally-occurring beta-carotene isomers, in relati~e amounts of at 122~t 40% 9-ci~ beta-carotene and less than abo~t 50% all-trans be~a-carotene, more typically comprising at least about 50S 9-cis beta-caxotene and less than ar equal to 40~ o~ all-trans-~2ta-carotene. The amount of alpha-carotene in these preparations ~sually is less tharl about 109~ of the total amount of carotene present. As the preparations are derived fro~ a natural sQurce, con~niently algae such as Dunaliella species, the compositions may f~rther comprise other:carotenoids (generally : about 2% ar less) and o~her cis-~eta carotene isamers (generally about 3~ or less). The compositio~s are s~stantially free o~ organic solvent and thus are suitable ; . ~or administration to hu~ans or other ani~als. I .
In other embodiments the compositions, including ~-pharmaceu~ical compositions, proYided by the invention comp~ise at leas~ about 60% 9-cis ~eta-carote~e a~d less than js or equal to 25~ all-trans beta-caro~ene, and in some cases the ~,.
be~a-carotene may be 75S g-cis beta-carotene or higher.
I 35 F~rmulations o~ high purity 9-cis be~a-carotene are j particularly useful for oral delivery.
WO 94/10t40 ~ 7 ~ ~ PCr/US93/10314 ~ ' The high purity natural beta-caro~ene preparations may be combined with pharmaceutic::ally acceptable carriers, prese~ratives, vitamin supplements or other medicinal~ agents in a variety of formulatic:ns and dosages for administration to humans or other znimals, such as livestock, as ph~rmaceutical agerlts or as dietary supplements. The formulation ar~
typically a capsule, liquid, tablet or powder.
In yet other aspects the inYention provides convenient and economical methods for purifying beta-carotene, including the g-cis isomer of beta-carotene, from plants.
Plant material, such as algae, is extracted with a solvent or mixture of solYents, typically an organic solvent such as hexane, petroleu~ ether~ cyclohexane, ethyl acetate, e~hanol, etc. to produce a crude mixture of car~tenes. The sol~ent is removed ~rom the extr~ct znd the extract is then r~dissolved in a non-polar solvent such as hexane, petroleum eth~r, cyclohexane, etc. and chro~at~graphe~ on a column o~
deacti~ated alu~ina. Fractions containing ~he purified beta-carotene are then collected fro~ the colu~n.
2 0 To produce high-purity 9-cis 1 somer of beta carotene, in one me~od t~e high-purity natural beta- ::aro~ene ::ollected from the colu~n is flsrther proc~ssed. Typically the puri~ied ~eta-carotene is dissolved in a non-polar sol~ren~ at about 35-55 C to for~ a sattlrated solution, which is then chilled to crystallize out the all-~rans beta~caxotene portic: n . The solvent is ~hen remoYed froIQ the supernatant sol~ti~n to yi~ld a preparation substantially enriched an 9- j cis beta-carot*ne. The procedure may be repeated, i.e~, the ??
step~ of dissolving in warm rlon-pol2r solvent, chilling to '.
crystallize the all-trans b~ta-CarQtene~ separ~ting the ?r solution fr~m the crystals ~ and removing the solven~ to yield a preparation further enriched in 9 cis beta ::arotene.
.
l~ ~
WO 94/l0140 .~ 1 ~ 7 S 2 ~ PCI/US93/10314 t` `
Brief PescriPtion o~ th~ p~ çs ` !~
Fig. 1 is a chromatogram depicting highly enriched 1-natural ~eta-carotene a f ter initlal fractionation . ¦.
Fig. 2~ is a chromatogram which shows the same material as in Fig. 1, but with the ,B-caro~ene isomers resolved by use of a Vydac column. ~igs. 2B and 2C ~re a c:hromatograms from su~sequent purification steps to produce preparations enriched for the 9-cis isomer and all-t~ans isomer, respectively, of beta-carotene.
i ,~ Des~ri~on of_the SDeC ' ~iO Embodiments ;~ 15 The present invention provid~s methods for the preparation of~ highly purified natlaral beta-caro~ene and compositions con~aining the hi~h purity natural be~ carotene.
The methc~ds generally: involve the separatlon of the beta- :
carotene fro~ the neutral and polar lipids of the crude pla2lt extract and removal o f o~qen-c:ontaining carotenoids.
Alsc) provid~d are D~etho~ls ~or the preparation of and con~posi~ions of nat~ral high purity 9-Ci5 isomer of beta c:aro~ene. The compositions may be for~ulated and used in a num~er of ways, including, among oth~rs, as dietary suppl~ments for hu~ans and other animals, and in the pre~ention and treatment o~ certain neoplastic c:onditions. ~-The beta carotene containing composi~ions of the ' invention ~ay be prepar d froD~ a Yariety o~ plan~ ma~erials, s~lch as algae, palms, veget~bles such as spinach, broccoli, alfalfa, and other plants. This method may also be used to p-lrify ~Ea~ is~er froDl carrots and sweet potatoes, e~c.
. Prefera~ly the plants are algae. Among the algae, preferred . classes are Chlorophyta (green algae), of which the preferrec~
genus is Dunaliella. Ot:her genera may be used so long as c:arotene can be produc~d in relatively large ~uan~ities.
~ `'i,~`, WO94/tO140 i~1 4 ~ ~ 2 S PCT/US93110314 Cultivation techniques may ~ignificantly incxease the amount .
of carotene present in each algal cell.
Typically, the algae are raised in shallow tanks, bioreactors, man~made or natural ponds at a wide range of s temperat~res, e.g~, from 15-~O~C, more preferably about 25-45C. Preferably the c~lture medium is salt water, but fresh water can also be used. Fresh w~ter may be made salin.o by the addition of salt a~ a culture medilL~. The medium ma~ be supplemented by the addition of nitrate, pho~phate, bicarbonate, iron and trace minerals. ~rotocols for the large scale propagatian of algae are described in, ~or example, A.
Richmond, andbook of-Microalqal M~ss ~ul~l~, CRC Press, Boca Raton, Fl., (1986), which is incorporated herein by reference.
When the algal culture reaches the desired density , e . g ., a~out û.25 to 0.5 grams dry weightJlite~, as determined ~y absorba~ce, the algae are har~rested from the tank or pond by pumping out the wat~r slurry contain~ the dispersed alyae.
T~e slurry may be passed throu~h screens which are su~ficiently coarse to allow algae through but which remo~re lar~er unwanted obj ects .
The slurry is then concentrated in algal content, typic:ally by evaporation, centrifugatiorl, flocculation, ultrafiltration, flotation, etc~ to allow re~oval o~
unnecessary water. In one embodi~ent, following concen~ration o~ the slu ~ the salt is largely re~oved by addition of fresh h~t water and u~tra~iltration. This also breaks the algal cells, libera~ing ~he beta-carotene. The concPntrate is then centxifuged in a suitable continuous flow centrifuge, such as a cream separator, to yield ~n upp~r (crea~) phase of carot ne and lipid, which is continually re~oved. This is dissol~ed in : a suitabl~ solvent, such as hexane, cyclohexane, petroleum ether, etc. as descri~ed below.
In another embodi~ent, the algal material is dewatered by centrifu~ation, ultrafiltration, etc., and the carotenes are then extracted fro~ the algal or other plant preparation by use of a suitable organic solvent. The extraction and subseouent purification procPdures are W094/lOt~O 2 1 ~ 7 2 ~ 3 PCT/US93/1~314 j~
typically performed under low light intensity and under vacuum or an atmosphere of inert gas (e~g., nitrogen) to maxi~ize recovery of non-oxidized carot2nes. The extraction~solvent or solvent mixture may be organic, ~uch as hexane, hexanes, ¦`
pentane, heptane, octane, petroleum ethers, cyclohexane, ethyl acetate, acetone, or ethyl alcohol, or inorganlc, ~uch as, for example, carbon dioxide as a liquid or as a super-critical ~luid.
The solvent is then removed from the crude extract, typical}y by eqraporating under vacuum, and ~he crude extract is dissolved in ~ minimum amount o~ a suitable non-polar solvent, such as hexane, petroleum ether~, cyclohexane, etc.
The solution of extracted and re-dissolved carotene is then applied to a chromatographic colu~n of alumina, preferably alumina which has been deactivated (partia~ly or totally), or silicic acid, FLORISI~9 (magnesiu~ sllicate) or the like. The alumina is deacti~ated by suspending it in aqueous ethanol (ethyl alcohol:water at 7Q:30 v/~) or si~ilar procedura. Ihe alumina is then packed into the column as a 1~0 water/alcohol slurry~ The colu~n is typically washed to remove the water, s~ch as with ethanol, then wit~an ethan~l/hexane mixture, e.g., 40S ethanol:60~ hexane. Several column volumes o~ a suitable non-polar solvent, e.g., hexane, petrol~um ethers, etc. followed by additional washes;
typically at least about five to six column ~olu~es, o~ a 100%
non-polar solvent, such as hexane, pentane, heptane r octane, petroleum ethers, e~c., but preferably hexane, to completely remove any remaining ethaAol from the columnO
The resolubili~ed carotene'extract is then applied to th~ column. The extract is washed throu~h the column, typically using the same non-polar solvent as that in which it is dissolved, preferably hexane. Fractions containiny t~e m~in band of orange-red car~tene are then collected and the salvent removed,:typically by eYaporation and preferably in ~ ~35 vacuo. The fraction then con~alns the high purity na~ral : : beta-carotene. By "high purity ha~ural beta-caro~ene" as used ~: herein is meant a composition which comprises fro~ 30-60% all-I ~
~: .
W094J10140 21A~ 8æs PCl/USg3~10314 '- ' trans-beta-carotene, 40-70% 9-c~s-beta-carotene, up to a maximum of about 10% alpha-carot~ne, and up to no more than , about 6~ of other mono-cis and dl-cis beta-caxot~ne ~somer~ ~ , j combined. A typical preparation of high purity na~ural beta- !
1 5 carotene of the invention comp~i6es 50S 9-cis-beta~arotene, 40% all-trans-beta-carotene, 5~ alpha carotene, 2% other 1 carotenoids, and 3% other cis-~eta-carotene isome.rs.
3 After elution of the beta-carotene fraction from the column, elution with the same solvent i5 continued a~d subsequent fractions immedia~ely following the main color band are collected, with another four to five column volu~es being I collected to remove virtually all o~ the pale yellow remaining ! caxotenoids, including some beta-carotene. This is useful as I a pro-vitamin supplement or ax a natural coloring agent.
! 15 Periodically ~he column may be cleansed to remove any more polar carotenoids, plant lipids and chloropAyll from the column, typically by bacX-wa5hing wi~h a polar solvent such as acetone and~or ethanol. T~is wash i~ fur~her processed by evaporation to recover solvent. Salids ~ay be discarded or used in animal feed or as a health fo~d. The colu~n is then washed wikh 40S ethanol/non-polar solvent, f~llowed by pure non-polar solYent as described above to r~store it ~or further c~rotene purification~ Periodically the ` build-up of green pigment and a}gal lipids cannot be eluted2S and the column may need to be repacked with fre~h alumina as I described abo~e.
¦ The natural high purity beta carotene preparation ! prepared as ab~ve may be us~d to produco co~positions which ! comprise even.further more highly purified 9 cis isomer beta-~axotene~ By "high purity natural 9-cis beta-carotene" as used herein is meant a mixture of alpha- and beta-carotenes derived fr~m a plan~ source which comprises greater than 60%
9-cis-~eta-c~rotene. Preferably the natural 9-cis-beta- .
,j carotene comprises at lea-~t 70% of the composition, more j 15 preferably at least about 80%, and most preferably 90~ or more. Typically the ratio of ~-cis-beta-carotene to al}-~j 2 1 4 7; ~ ~
WO ~4/10140 PCT~US93/10314 9 ~`.
trans-beta-carotene will be greater than or equal to 3 . O
preferably at le~st abc:ut 5.0~
The high-purity natural 9-cis-~eta-c:aro~erre is produced by dissolving the high purity beta-carotene preparation in the minimal amount of warm (typically 40-50 C) non-polar solvent needed to ~olubilize the beta carotene. A
variety of non-polar solvents may be used, such as, for example, hexane, ~yclohexane, pentane, heptane, octane, petroleum ethers, but preferably hexane. Thi~ solution is chilled, typically to about -20C, to cause the preferential c~ystalli2ation of the all-trans is~er of beta-G2rotene. The crystal5 are then separated from the supernatant solu~ion by any of the usual separation me~hods, e.g,, filtration, centrifugation, decanting, etc. The r~maining supernatant solution is then evaporated to re~o~e ~he sol~ent, leaving a carotene preparation which co~prise. highly p~rified 9-cis-beta-carotene isomer. The final p~eparations will be substantially free o~ the orsanlc solvent. By su~stantially ~ree is meant that t~e preparation will conta~n no or little txace of organic solvent, and in any event will not exceed that amount permitted by regulatory aqencies for.
administration to humans. To remove additional all-trans beta-carotene and produce a more highly puri~ied 9-cis-~eta carotQne preparation, the supernatant solution cont:ainir~g the 9-cis-is~mer can be re-e~raporated " ~e-dissol~ed in a minimal amount of solvent as abo~re, and re-crystalliz~d by chilling.
The resulting all-txans beta carotene by~prod~ct is typlcally 75gc or more pure, and can be used for a variety of purposes, such as~, for `example, a source of vitaaQln AJI a 3 O natural coloring produc:t, or a5 a disease preventati~e or ..
reatment.
The compc~sitions of hiqh-purity natural beta- -carotene and 9-cis beta-carotene find a wide variety of uses, including as pharmaceuticals and as dietary ~ritamin 3 5 supplements .
Dependinq on the intended mode af administ_ ation and the intended use, the compositians may be in the for~ of ~ 5 ~ ~:
~n 94/1~140 PCT/US93~0314 ~"
solid, semi-solid or liquid dosage forms, such, for example, as tablets, capsules, pills, microbeads, beadlets, powders, ~ granules, crystals, liquids, suspensions, liposomes,~etc., j preferably in unit-dosage form~ suitable for administration of relatively precise dosages. The compositions may include a conventional pharmaceutical carrier or excipi nt and, in addition, may include other medicinal agents or vitamins, pharmaceutical agents, carriers, etc.
The high-purity natural beta-carotene and 9-c~s beta-carotene of the invention may be ad~inistered in relatively large amounts without seriQus side effects, althou~h indiscriminate use may produce yellowing of the sXin.
In cases where the compositions are administered to preven~
the emergence of disease in subjec~ susceptible to certain ~ 15 types of neoplasia, cardioYascular disease, etc., ~r to those 9~ suf~ering ~rom only mild or borderline disea~e, the dose may ~e adjusted accordingly to lower ~aintenanc~ levels.
For solid compositions, as would be appropriate for oral ad~inistration, ~he high-purity natural beta-carotene and 2~ ~-cis beta-carotene c~n be provided separately or may be compou~ded with conventional nontoxic solid carriers such as, for example, pharmaceutical grades o~ mannitol, lactose, s~arch, magnesium stearate, tal ~ , cellulose, glucose, sucrose, magnesium carbonate, and the liXe. Such compositions take the form o~ solutions, suspensions, tablets, pills, ~apsules, powders, granules, cry~tals, sustained-release ~ fo~mulations, and the like, and ~ay contain about 10-100~ ~
ac~ive ingredient, prefera~,ly about 25-goS.
. I Liquid:pharmaceutically~administrable co~posi~ions ~ 30 can, for example, be prepared ~y dissolving the hi~h-purity ¦ natural beta-carotene and/or 9-cis beta-carotene and op~ional. ,~
! pharmacautical adjuvan~s in a carrier for suspPndin~ or ¦ dissolvinq, such as, for exa~ple, mineral or vegetable oil and Y~ the like, to thereby form a solution or suspension. The 3 5 concentration ~ f the high-purity natural ~eta-carotene or 9-Z cis ~eta-carotene in 'chese fon~lulations can vary ~idely, and will be selected primarily by intended use, viscosities, et~., ~, .. 1`,`.,.`.
" ```~` 2 .1. 4 7 ~
W094/tOl40 PC~/US9~/~0314 in accordance with the particular mode of administration selected.
As a dietary supplement the high-purity natural beta-carotene or 9-cis beta-carotene may be supplied as an oil, ~suspended in a capsule, ~eadlets, etc. or incorpor~ted directly into foodstuffs as a con~enient means of administration .
If desired, the phar~aceutical composition to be administered may also contain minor amounts of nontoxic auxiliary subs~ances such as anti-oxidants, e.gO, vitamin E
I (tocopherol~, BHA, BHT, pH buffering agents and the like, for ¦ example, sorbitan monolaurate, triethanolamine, sodiu~
! a~etate, triethanolamine oleate, etc. Actual methods of I preparing such dosage ~orms are known, or will be apparent, to ¦ 15 tho5e skilled in this art; for example, see Remington's Pharmaceutical Science, 17th ed., Mac~Pu~lishing Co~pany, Easton, PA (1985~, which is incorporated her~in by re~er~n~e.
The composition or fo~mulation to b~ ad~inistered will, in any èv~nt, con~ain a ~uantity o~ the high-purity natural beta-carotene and/or 9-cis beta carotzne in an amount effective to ~ alleviate or amaliorate the s~mptoms of disease or inhibit : their em~rgence in ~he subject.
. The pur~ied ~eta carotene co~positions of the in~ention may be administered ~cr a variety of therapeutic or 2S prophylactic uses to humans or in~veterinary applications.
The compositions may be used as a vitamin preparation, alone or in conjunction wit~ other ~itamins, to supple~en~ dietary intake of vitamin A and thus to treat or pr~ven~ conditions ~ i ` associated with vita~in A insu~ficiency. As beta-carotene, and particularly 9-cis beta-carotene, are anti-oxidants~which can function in lipid environments at the low partial pr~ssures of o~ygen found in animal and hu~an tissues, the compositions of ~ the inven~ion can also be used in preventîon or treatmen~ of a :~ varieey of diseases or pathologlcal conditions associated with ~:35 free radicals and:lipid auto-oxidation.
In other uses the high-puri~y natural be~a-carotene or 3-cis beta-carotene are a~inistered theraDeutically or :' :
~, ~
i.` ,'~ ~ 4~
~ WO94/10140 PCT/US93/10314 `"! 12 prophylactically for a variety of cancers, particularly epithelial cell cancexs. Beta-carotene preparations have shown significant protection against various tumors in ~c~ animals. Among the animal models of cancer which established i~' 5 a protective or other beneficial effect of bet~-c~rot2ne are sXin cancers, includinq thos~ induced by ultraviolet light (~pstein, ~hotochem. Photobiol. 25: 211 ~1977), and ~athews-.~ Roth, in Current ChemotheraDY_and In~ec~ Diseases, eds.Nelson and Grassi, Amer. Soc. Microbiol., Wash. D.C., p. 1503 , (1980)), breast cancers (Santamaria et al., Med. ~iol~
Environ. 12:533 (1984) ), fibrosarco~as (Combs et al ., utr.
Cancer 12:371 (1989) j, epidermoid ~rcinomas (Shklar et al., ~utr. Cancex 12:321 (1989) ), gastric cancer (Santamaria et ;~ al , J. Nutr. Growth Can~er. 4:175 (1987) ), colon cancer i,.~ 15 (Santamaria et al., Pre~, Med. 18:603 (198g)), exocrine , pancreas neoplasias (Wouterson et al., 53CÇ9~ 42:79 19%8) ), ~ladder cancer (Mathew~-Roth et al., ~D~,~Y 48:177 tl9~1) ), and ~irus induced cancer tSei~ter et al., J. ~Jatl.
.,i~ ~ 78:1211 (19~2)).
ao Accordingly, the beta-caxotene and/or 9-cis beta carotene pr~parations of the invention are indicated for use ;~ in therapeutic methods .~or a variety of cancers, including in .~ humans. Beta-carotene preparations haYe been shown to be useful in treating, inhibiting or o~erwise preventing tu~nors ~2S in humans~ including lung canc~rs, such as s~amQus cell .1 c:arcinoma, cancers of the gastrointestinal trac:t, e.g., mouth (Stich et al~, ;rltl J. Cancer 42:195 (1988) and Stich et.al., ',~ in Carotenoids: C~emistry:_and 8iolo~, eds. ~rins~cy et al., ~,-~3 I Plenum Press, p. ~13 (19'~0) ~, pharynx, larynx (Plac3cerras e~
0 al., Amer. J E~idemi ol. 123: 980 (1988) ), esophagus, stomac:h 4:
Graham et al., ~a~5~n~ 13: 19 ~1990)), colon (Santamaria et al., ~ 13: 603 (1989~, Te~Dple et al., J. Natl .
can~e~ s~: 78 :1211 (1987) and Graham et al., ~, . Natl . canc:e-Inst~ 61:709 (1978) ), rectum, bladder (Comstoc3c et al., Amer.
.~5 J. Clin. Nut-. 53 :260s (1991~, Tyler et al., Eur. J._Sur~. :
5~ k 12 : 35 (1986), and Mathews-Roth e~ al ., ~ 48 :
~i 177 (l991) ) and cer~ix (Palan et al., Ame~. J. Obste~.
~,'j 1 4 7 ~
WO94/~0140 PCT/US931~10314 ~3 .~ Gynecol. 161: 1649 ~1989~. Beta carotene has also been shown effi.cacious in preventinq or ~nhibiting ~kin cancers ~uch as melanoma (Comstock et al., supr~) and epider~oid cancers of ~ the head and nec~ (Shklar ~t al., Nut~, ~ançer 12:321 (1989)).
.~; 5 Carci.nomas of the secretory ylandsr e.g., pancr~s ~outerson ~ et al., Cancer Lett. 42: 79 (1988)), and breast (~asu, J.
:~ Amer. 5 ol.~ Nutr. 6: 451 (1987) and Santamaria et al., L~
.:~ Biol. Environ. 12: 533 (1984)), and mucosal dysplasias of the :~ oral ca~ity, oropharynx and tongue tMalaker et al., Clin.
~: 10 Invest. Med. 10: B113 (1987)) have also reportPdly been ";,1 treated by the beta-caroten~s. Each of the foregoing .. publications is incorporated by re~erence herein in its . entirety.
Thus, the highly pure beta-carotene and~or g-cis beta-carot2ne preparations of ~he ~nvention are particularly ,: use~ul in therapy or prevention o~ tumors which have been ``. shown to be at least partially re~pon~iv~ to less pure . preparations o~ beta-carotene. Because ~the ~-cis isomer is believed to be an e~fective anti-oxidant co~pared to other isomers o~ beta-carotene and ~ay be better~absorbed, preparations o~ this isomer are parti~larly preferred in the '~' the treatment or prevention of these tu~ors.
The hi~h-purity natural be~a-carotene and/or 9-cis ~ beta-car~tene compositions can also be applied to ~he skin or i `Z5 other tissues to diminish the effec~s of premature aging, e.g., damage t~ proteins a~d collagen tissue induced by e~p~sura to ultraviolet radi~tion,: such as with sunlight.
.~i Topical application of the beta-carotene prepa~ations to the .~ ~ s~in may be in the form of cremes, ointments, li~uidsi a~d the ~i~ 10 l.ike, ~r incorporated into cosmetics and toiletries.
L`~ Risk of cardiovascular disease, e.g., cardiac arrhythmias, myocardial infarct~ons, angina pectoris .~ (Riemersma et al., Lancst~ i:337 tl9~1)),~and~stroke can also be diminish~d by the high~purity natural beta-carotene or 9-:,'~;i l cis beta-carotene compasitions o~the invention.
:~ Other indications for the high-puri~y beta-carotene preparations of the in~ention incLude ;hose which have been ~4 1~
`' WO94/iO140 ~ 7~2 Pcr/us93~l0314 ,~, !
reported to benefit from treatment with less pure or synthetic beta-carotene preparations, ~uch as ~uchenne'~ muscular '.
. dystrophy (tPatsch et al., Clin, ~es. 33: 441A (1985)) and cataract (Jacques et al., ~m. J, Cl~. Nut~. 5~:352S (1991 ) ) . J
S Beta-carotene has also been reported to enhance T and B
lymphocyte proliferative responses (Bendich et al., J. Nutr.
,~ 116: 2254 ( 1986~ ), such as increased T cell effector functions,`'! in~::luding cytotoxic T cells , NK cells tPrabhala et al ., Cl in .
~es. 36:142A (1988)), production of interleukins~ to enhance .~10 anti-tumor Lmmunity (Tomita et al., J. ~atl ~Ca~. Ins~, 78:679 1987)), and to protect polymorphonuclear cells from damage by free radicals during destruction o~ bacteria tAnderson and Theron, World Re~. ~utr. ~ie~. (1989)).
The synthetic preparations of beta-carotene contain only the all-trans for~, whereas natural carotene from green ~ plant tissues con~ain a ~i~ure of iso~ers, and the ,~ compositions o~ the present invention are ~speci~lly high in the 9-cis isomer, which i5 believed to ~?a a better anti-xidant t~an the synthetic all~ iso~r. Mor~over, beta-carotene from natural sources ha~ been rep~?rted to be absorbed $ at least ten-fold greater ~om the gastrointestinal tract than ;~i the all-~3~ form. Ben-Amotz et al., ~. Nut.~ 119:1013 ; (198g).
~, The pharmaceutical compositio~s are intended ~or j;! 2S oral, }ocal, topical or p~renteral (i.~., intrav~nously, ~:~ subcutaneously, or intra~uscularly) administration f~r , prophylactic and/or therapeutic treatment. Preferably, the ~,t pharmaceutical compositions are administered orally. As ~:' ' ~ ' m~nt~oned abo~e, the 9-cis iso~er of beta-carotene is a better anti-oxidant and is better abs~rbed than all-trans beta-carotene~ $hes~ compositions may be sterilized by conventional, well Xnown sterilization techniques. The ~ ~ compositions~may contain pharmaceutically acceptable auxiliary `~l substances as required to approximate physiological conditions ' j?~, and as necessary to prepare compositions for con~enlen~
; administration, such an pH adjusting and bufferin~ agents, and delivery vehicles, for:example, vegetable or mlneral oil.
.,r ~ WO94~10140 .~1~ 7 8 ~ ~ PCT/US93/10314 Actual methods for preparing pharmaceutically administrable :;
compounds will be known or apparent to those skil~ed in the :
art and are described in detail ~n, for example, Remington's .. i.:
Pharmaceutical Science, sup~q.
Compositions of the inYention are administered to a host already suffering from a neoplasia or cardiovascular disease, as~described above~ in an amount:sufficient to cure or at least partially in~ibit the disease ~ and its complications. :An amount adequate to ~accomplish this: is ~10 : def ined as~a "therapeutically:e~fective~dose,~ Amounts effective for ~his use~will depend:on ~the severity o~ ~he disease and the weight a~nd gener l;state:~of~ the~patient being : :
treated, bu~ generally range fro= about:5 mg to about~2,000 mg `~
per day of high-purity natural beta-carotene or 9-cis beta- -:carotene per day,- wlth dosages:o~from~about~;lO~:mg to ~about: ~ :
SOO~ mg~ per day being more commonly used. ; Maintenance dosages~
over ~a: ~prolonged~period o~ ti~e may:be~adju5tèd as necessa ~ .
.~ It~=ust~be kept ~in ~ind that the:compo~itions of the pres~nt ~ invention:may be~=ployed~in~serious~disease~states,~that~is, ?~~ ~ life- ~ reatening:or:pote~ntial~ly life threàtening situations.~
.~ ; `In:such~cases, it is;~poss~ble ~nd may~be felt~desirable ~y~th:e ,'.
`tre~ating physician~to ~administer substantial~excesses:;o~these`
composi~ions. For~vèterinary:uses~higher:levels may be admlni~stered~ as ~nècessa~
~5~ Dete ~ lning;;~àctual~a=ounts~:~of~ ~ e~hlqh-purlty~
~ : natural beta~--carotenéi: and/or 9--cis :~ beta--carotene necessary to ;hf' ~ it or~ treat ~a'pa~tifcular~`~disease,~such~as~neoplasias~
ca.rdiovascular disease,~immune~disorders/~etc.~as describef~
a~o~ef will be throuf3h standàrd emplrical methfods ~hich:~are: ~.
. O~ wéll~kno ~ in:~thei~a ~.
i~ n~frophylactic~applications~co~posltions containin~
f~ ;~ the~high-purity~natùral~beta-~carotene~and/or 9-cis beta~
c~rotene.are~;~adminis~ered~:to~ a~:h st~suscept fle~ to~; ar ~ ~ cther~ise~at~:risk~of~ dl`saases~assoc~ated~vith~vitamin A~
P~ 5~ dafiCiency~fi~ffr~oxi~ation-ass~ `iated diseases~::to erihance~:~the~
patient~s own~capabi:lit~;~es;~àga~nst~the~dlsease~ Suc~ an~
~a i fU~` ` i de ined~:~t ~be~a~l'prophylac Lcally~effectlve~dose.
~ ~~_ ,` WOg4/10140 .~ 2S PCT/US93~/10314 In this use, the precise amounts again depend on the patient's state of health and wei~ht, but generally range from a~out 3 mg to about 500 mg per dayt more commonly from about lO mg to about 30 mg per day. Single or ~ultiple administrations of the compositions can be carried out with the dcse lev~Pls and pattern being selected by the treating physician or health ~ are specialist.
'`~ The compositions of the in~ention, including pharmaceutlcal compositions, may be administered alone or as adjunct therapy or prophylaxis. The compositions may be administered with, e.g., other anti-oancer or anti-cardiovasc~lar disease therapies, or as oomponents of dietary `i.j regimens.
The followin~ examples are provided by way of illustration, not limitation.
~AMPLE I
~ 2 ,~
~: Pre~a~ation o~ Hiqh_Pu~ity ~atural Beta-Carotene J This Example describes the preparation of high purity beta carotene.
Duna~ie~la sali~ was xaised in culti~ation ta~ks comprised of a paddlewheel system in 4' x lO' tanks, with ~ 4"
water level. The culture ~e~ium was 2.5 N -~alt water, with i.
O.~ ~ phosphate r 5 mM HC~3, 1 mM N03, iron and trace minerals ~-I / and ~aintained at a temperature of ab~ut 35C under controlled lighting conditions (six lOOO watt halide lights at lO~l2" 7 from surface). Nitrate limitation was used to induce c rotene ~s.
j~ production. When the culture rea~hed a density of O.2S grams dry wt/l, algae were harvested fr~ the culti~ation tanks and ~locculated using alum to form an algal slurry. The slurry ~35 was mixed wlth diatomaceous earth and vacuum filtered to remove most of the water, then treated ~ith hot (60~C) water and then made as dry as possible with vacuum. The resultin~
., WO 94/tOt40 .~ 1 4 7 ~ 2 ~ p~us93!~103l4 ¦ ~
~;1 cake was then extracted with hexane ~o r~move the crude carotene preparation.
The hexane solvent was then removed by evaporation under vacuum at 40-50C and the crude extract was re-dissolved ¦:
in the minimum amount of hexane possible. This s~lution was `.
. then applied to a 3" x 12 n chromatographic column prepared as follows: Activated alumina (aluminum oxide) of a chromatographic grade (Aldrich Chemical CO., Brockman grade I, acidic, about 150 mesh), wa~ deactivated by suspending it o~ernight in 2 volumes aque~us e~hanol at a mixture of 70 parts. ethyl alcohol to 30 parts water~ The de~ctivated alumina was then packed into the column as a slurry in the water~alcohol mixture. The slurry was then washed well with four ~olumes o~ abs~lute ethanol to remove ~he water, followed by a wash with two column ~olumes of 40~ ethanol in hexane.
. The column was then washed with hexane for at least ~i~e to ` six oolumn ~olumes to completely remove any re~aining ethanol.
Th~ crude carotene extract was then applied to ~he column in about 100 ml hexane and washed ~hrough the columr~
, ~ 20 with hexane. ~ fraction o~ 300 ~1 containing t~e ~ain band of ;~ oran~e-red carot~ne was collected and ~e sol-vent removed by vacuum evaporation. At this st~ge the beta-carotene was approximately 90-959~ pt~riîied, as shown in a representati~e chromatcgram a~ Fig. 1 using a Sup~lco colu~n which does not ;iil 25 resolve the varicus isomers of beta-carotene~ A similar preparation on a Vydac column, which does resolYe the be~a-carotene isomers, shows ~he beta-carotene is comprised of approximately 55% ~-cis isomer and about 45% all~trans isomer (Fig. 1 2~
~0 Elution: with hexane was continued into a different container i~media~ely after the mai.n color band, with ~wo liters ~eing collected to remoYe virt~lally all of the pale yellow material, prlmarily beta-carotene with other carotenes ~ a~d carotenoids, which was kept as a separate by-produc- of .~ 35 50 ~0% pure beta-carotene.
~:. Periodically, the column was cleansed by bac~-washing wi~h a polar solvent, typically acetone or e~hanol, ~o ' " '; ` '' `i ',` ~, '., ' ! 'j '.
,7 ~ 2~ ~ ~
~; WO94/10140 PCT/US93/10314 ~-.; ;,; .
remove oxy~genated carotenoids, plant neutral liptds and chlorophyll from the top of the column. This material may contain small amounts of astaxanthiin and/or can~haxanthin which are valuable in fish feed a~ colorants for armed salmon ~i~ 5 and.trout. The column was wa5hed as be~ore Wi~l 40S
etha~ol/hexane solvent and pure hexane to restore it for ,~ further carotene purification. Periodically, as needed by the ~ build up of chlorophyll and other lipids which could not be : eluted as above, the top 2 n_3 n of the column was re-pac~ed with fresh alumina.
The resulting preparation of high purity betao c~rotene was evaporated to remove solven~ and yielded ~bout 95% beta carotene and 5% alpha-car~tene, as shown in Fig. 1.
Purity w~s confir~ed by thin layer chromatography and ~PLC.
!i i ~ii EXAMPL~ I~
7'~ ~O ~roduc~ion oP ~i~h ~yiritY ~ Carotene :j, , .
. This Example describes the production o~ beta-~ carotene enri ::heid in the . 9-cis iso~er fro~ the high purityi)~ beta-caxotene prepared as described ln Example I.
2 ~ Hi~h purity beta-carotene fro~ Example I was dissolved in a min~t~l amount of warm ~abs:~ut 40 50 ~C~ hexane ~,'! t:o achieve sa'curatic~n. The solution wast then chill~d, typically to ab~ut -20 C, which caused the preferential c~ tailization~of the trans-isomer of beta-carotene. 5~e .!,' 3 0 crystals were theri separated from the supernatant ss:llution by ~'?' ~iltrat:ion throu~h a hydrophobic 0. 22 ~ nyloll mem~rane filter (Micron Separations , Inc ., Ca~ridge , HA) . C~romatograD~s of `~ representatlve preparations of the supernatant enric:hed in lthe s-c s isomer (approximately 75-80S 9-cis and 15-20~ all-trans) and OL' the crystals containing ~he all-~ isom~r ~t,'~ tapproximately 80-859c all-trans and 10-15S 9~ i5) are shown in Figs. 2B and 2C, respectively.
j~ .
~ 't WO 94/tO140 ~ l 4 7 ~ PCr/US93110314 The supernat~nt solution was then evaporated to dryness under vacuum, at abaut 40 C and under low light (as .
with all Ol' the purification steps described herein) to remove the heacane, leaving a carotene preparation which was ;~ 5 substantially enriched in t~e. 9-~is isomer. Typical yield of ; the 9-cis isomer from these preparations was approximately 2-3 grams. Experience with these purification p~ocedures indicate they can readily be scaled up to pilot and production levels.
EXAMPLE I~I
apsule_Formulation ; -This Example describes ~ormulation of a dietary compcsition containing beta-carotene of the invention which is intended for oral aclministration in capsule fo~.
Ing~edient~
Hi~h Purity Beta-Carotene 3 0 mgs Vitamin E 400 I~.
Vitamin C S~o ~s The above ing~re`dients are coml:~ined and pl~ced into a gelatin capsule suitab}e for administration to humans.
.' ' ~;
. . i.
It is e~ident from the above that the subject invention provides hiqh-purity natural beta-carotene and 9-cis ~,~
beta-caro~ene which find use as dietary supple~n~nts for humans .. ¦ and other animals, an~ in the t~erapy of a number of diseases, 7.":
including cartain neoplasias, and in the prevention of other diseases, such as cardiovasc:~llar disease. FurtherTQore, t~
' in~rention pro~,rides economical meth~ds: to prepare the high-purity natural beta-carotene and 9-cis be~a-carotene from plant ma~ter, conveniently from large scale alga propagation.
rXI
~' `1 ~3 ~ ,VO94/10140 ~ 1~ 7 8 2 ~ PCT/VS93/10314 ~0 All publications and patents mentioned ln this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent5 are herein incorporated by reference to the same extent as if each individual publication or patent wa~ specifically and indiYidually indicated ~o be incorporated herein by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of' clarity of understanding, it will be ok,vious that certain changes and mc,difications ~ay be practlced within the scope of the appended claims.
,.
~-.
. ` .
~;
..
~' . ! . ` i ~ !
~ : ~
.~.'~ '.
.
. . .
';J
.. ,.:
,~ ~
:
~i 177 (l991) ) and cer~ix (Palan et al., Ame~. J. Obste~.
~,'j 1 4 7 ~
WO94/~0140 PCT/US931~10314 ~3 .~ Gynecol. 161: 1649 ~1989~. Beta carotene has also been shown effi.cacious in preventinq or ~nhibiting ~kin cancers ~uch as melanoma (Comstock et al., supr~) and epider~oid cancers of ~ the head and nec~ (Shklar ~t al., Nut~, ~ançer 12:321 (1989)).
.~; 5 Carci.nomas of the secretory ylandsr e.g., pancr~s ~outerson ~ et al., Cancer Lett. 42: 79 (1988)), and breast (~asu, J.
:~ Amer. 5 ol.~ Nutr. 6: 451 (1987) and Santamaria et al., L~
.:~ Biol. Environ. 12: 533 (1984)), and mucosal dysplasias of the :~ oral ca~ity, oropharynx and tongue tMalaker et al., Clin.
~: 10 Invest. Med. 10: B113 (1987)) have also reportPdly been ";,1 treated by the beta-caroten~s. Each of the foregoing .. publications is incorporated by re~erence herein in its . entirety.
Thus, the highly pure beta-carotene and~or g-cis beta-carot2ne preparations of ~he ~nvention are particularly ,: use~ul in therapy or prevention o~ tumors which have been ``. shown to be at least partially re~pon~iv~ to less pure . preparations o~ beta-carotene. Because ~the ~-cis isomer is believed to be an e~fective anti-oxidant co~pared to other isomers o~ beta-carotene and ~ay be better~absorbed, preparations o~ this isomer are parti~larly preferred in the '~' the treatment or prevention of these tu~ors.
The hi~h-purity natural be~a-carotene and/or 9-cis ~ beta-car~tene compositions can also be applied to ~he skin or i `Z5 other tissues to diminish the effec~s of premature aging, e.g., damage t~ proteins a~d collagen tissue induced by e~p~sura to ultraviolet radi~tion,: such as with sunlight.
.~i Topical application of the beta-carotene prepa~ations to the .~ ~ s~in may be in the form of cremes, ointments, li~uidsi a~d the ~i~ 10 l.ike, ~r incorporated into cosmetics and toiletries.
L`~ Risk of cardiovascular disease, e.g., cardiac arrhythmias, myocardial infarct~ons, angina pectoris .~ (Riemersma et al., Lancst~ i:337 tl9~1)),~and~stroke can also be diminish~d by the high~purity natural beta-carotene or 9-:,'~;i l cis beta-carotene compasitions o~the invention.
:~ Other indications for the high-puri~y beta-carotene preparations of the in~ention incLude ;hose which have been ~4 1~
`' WO94/iO140 ~ 7~2 Pcr/us93~l0314 ,~, !
reported to benefit from treatment with less pure or synthetic beta-carotene preparations, ~uch as ~uchenne'~ muscular '.
. dystrophy (tPatsch et al., Clin, ~es. 33: 441A (1985)) and cataract (Jacques et al., ~m. J, Cl~. Nut~. 5~:352S (1991 ) ) . J
S Beta-carotene has also been reported to enhance T and B
lymphocyte proliferative responses (Bendich et al., J. Nutr.
,~ 116: 2254 ( 1986~ ), such as increased T cell effector functions,`'! in~::luding cytotoxic T cells , NK cells tPrabhala et al ., Cl in .
~es. 36:142A (1988)), production of interleukins~ to enhance .~10 anti-tumor Lmmunity (Tomita et al., J. ~atl ~Ca~. Ins~, 78:679 1987)), and to protect polymorphonuclear cells from damage by free radicals during destruction o~ bacteria tAnderson and Theron, World Re~. ~utr. ~ie~. (1989)).
The synthetic preparations of beta-carotene contain only the all-trans for~, whereas natural carotene from green ~ plant tissues con~ain a ~i~ure of iso~ers, and the ,~ compositions o~ the present invention are ~speci~lly high in the 9-cis isomer, which i5 believed to ~?a a better anti-xidant t~an the synthetic all~ iso~r. Mor~over, beta-carotene from natural sources ha~ been rep~?rted to be absorbed $ at least ten-fold greater ~om the gastrointestinal tract than ;~i the all-~3~ form. Ben-Amotz et al., ~. Nut.~ 119:1013 ; (198g).
~, The pharmaceutical compositio~s are intended ~or j;! 2S oral, }ocal, topical or p~renteral (i.~., intrav~nously, ~:~ subcutaneously, or intra~uscularly) administration f~r , prophylactic and/or therapeutic treatment. Preferably, the ~,t pharmaceutical compositions are administered orally. As ~:' ' ~ ' m~nt~oned abo~e, the 9-cis iso~er of beta-carotene is a better anti-oxidant and is better abs~rbed than all-trans beta-carotene~ $hes~ compositions may be sterilized by conventional, well Xnown sterilization techniques. The ~ ~ compositions~may contain pharmaceutically acceptable auxiliary `~l substances as required to approximate physiological conditions ' j?~, and as necessary to prepare compositions for con~enlen~
; administration, such an pH adjusting and bufferin~ agents, and delivery vehicles, for:example, vegetable or mlneral oil.
.,r ~ WO94~10140 .~1~ 7 8 ~ ~ PCT/US93/10314 Actual methods for preparing pharmaceutically administrable :;
compounds will be known or apparent to those skil~ed in the :
art and are described in detail ~n, for example, Remington's .. i.:
Pharmaceutical Science, sup~q.
Compositions of the inYention are administered to a host already suffering from a neoplasia or cardiovascular disease, as~described above~ in an amount:sufficient to cure or at least partially in~ibit the disease ~ and its complications. :An amount adequate to ~accomplish this: is ~10 : def ined as~a "therapeutically:e~fective~dose,~ Amounts effective for ~his use~will depend:on ~the severity o~ ~he disease and the weight a~nd gener l;state:~of~ the~patient being : :
treated, bu~ generally range fro= about:5 mg to about~2,000 mg `~
per day of high-purity natural beta-carotene or 9-cis beta- -:carotene per day,- wlth dosages:o~from~about~;lO~:mg to ~about: ~ :
SOO~ mg~ per day being more commonly used. ; Maintenance dosages~
over ~a: ~prolonged~period o~ ti~e may:be~adju5tèd as necessa ~ .
.~ It~=ust~be kept ~in ~ind that the:compo~itions of the pres~nt ~ invention:may be~=ployed~in~serious~disease~states,~that~is, ?~~ ~ life- ~ reatening:or:pote~ntial~ly life threàtening situations.~
.~ ; `In:such~cases, it is;~poss~ble ~nd may~be felt~desirable ~y~th:e ,'.
`tre~ating physician~to ~administer substantial~excesses:;o~these`
composi~ions. For~vèterinary:uses~higher:levels may be admlni~stered~ as ~nècessa~
~5~ Dete ~ lning;;~àctual~a=ounts~:~of~ ~ e~hlqh-purlty~
~ : natural beta~--carotenéi: and/or 9--cis :~ beta--carotene necessary to ;hf' ~ it or~ treat ~a'pa~tifcular~`~disease,~such~as~neoplasias~
ca.rdiovascular disease,~immune~disorders/~etc.~as describef~
a~o~ef will be throuf3h standàrd emplrical methfods ~hich:~are: ~.
. O~ wéll~kno ~ in:~thei~a ~.
i~ n~frophylactic~applications~co~posltions containin~
f~ ;~ the~high-purity~natùral~beta-~carotene~and/or 9-cis beta~
c~rotene.are~;~adminis~ered~:to~ a~:h st~suscept fle~ to~; ar ~ ~ cther~ise~at~:risk~of~ dl`saases~assoc~ated~vith~vitamin A~
P~ 5~ dafiCiency~fi~ffr~oxi~ation-ass~ `iated diseases~::to erihance~:~the~
patient~s own~capabi:lit~;~es;~àga~nst~the~dlsease~ Suc~ an~
~a i fU~` ` i de ined~:~t ~be~a~l'prophylac Lcally~effectlve~dose.
~ ~~_ ,` WOg4/10140 .~ 2S PCT/US93~/10314 In this use, the precise amounts again depend on the patient's state of health and wei~ht, but generally range from a~out 3 mg to about 500 mg per dayt more commonly from about lO mg to about 30 mg per day. Single or ~ultiple administrations of the compositions can be carried out with the dcse lev~Pls and pattern being selected by the treating physician or health ~ are specialist.
'`~ The compositions of the in~ention, including pharmaceutlcal compositions, may be administered alone or as adjunct therapy or prophylaxis. The compositions may be administered with, e.g., other anti-oancer or anti-cardiovasc~lar disease therapies, or as oomponents of dietary `i.j regimens.
The followin~ examples are provided by way of illustration, not limitation.
~AMPLE I
~ 2 ,~
~: Pre~a~ation o~ Hiqh_Pu~ity ~atural Beta-Carotene J This Example describes the preparation of high purity beta carotene.
Duna~ie~la sali~ was xaised in culti~ation ta~ks comprised of a paddlewheel system in 4' x lO' tanks, with ~ 4"
water level. The culture ~e~ium was 2.5 N -~alt water, with i.
O.~ ~ phosphate r 5 mM HC~3, 1 mM N03, iron and trace minerals ~-I / and ~aintained at a temperature of ab~ut 35C under controlled lighting conditions (six lOOO watt halide lights at lO~l2" 7 from surface). Nitrate limitation was used to induce c rotene ~s.
j~ production. When the culture rea~hed a density of O.2S grams dry wt/l, algae were harvested fr~ the culti~ation tanks and ~locculated using alum to form an algal slurry. The slurry ~35 was mixed wlth diatomaceous earth and vacuum filtered to remove most of the water, then treated ~ith hot (60~C) water and then made as dry as possible with vacuum. The resultin~
., WO 94/tOt40 .~ 1 4 7 ~ 2 ~ p~us93!~103l4 ¦ ~
~;1 cake was then extracted with hexane ~o r~move the crude carotene preparation.
The hexane solvent was then removed by evaporation under vacuum at 40-50C and the crude extract was re-dissolved ¦:
in the minimum amount of hexane possible. This s~lution was `.
. then applied to a 3" x 12 n chromatographic column prepared as follows: Activated alumina (aluminum oxide) of a chromatographic grade (Aldrich Chemical CO., Brockman grade I, acidic, about 150 mesh), wa~ deactivated by suspending it o~ernight in 2 volumes aque~us e~hanol at a mixture of 70 parts. ethyl alcohol to 30 parts water~ The de~ctivated alumina was then packed into the column as a slurry in the water~alcohol mixture. The slurry was then washed well with four ~olumes o~ abs~lute ethanol to remove ~he water, followed by a wash with two column ~olumes of 40~ ethanol in hexane.
. The column was then washed with hexane for at least ~i~e to ` six oolumn ~olumes to completely remove any re~aining ethanol.
Th~ crude carotene extract was then applied to ~he column in about 100 ml hexane and washed ~hrough the columr~
, ~ 20 with hexane. ~ fraction o~ 300 ~1 containing t~e ~ain band of ;~ oran~e-red carot~ne was collected and ~e sol-vent removed by vacuum evaporation. At this st~ge the beta-carotene was approximately 90-959~ pt~riîied, as shown in a representati~e chromatcgram a~ Fig. 1 using a Sup~lco colu~n which does not ;iil 25 resolve the varicus isomers of beta-carotene~ A similar preparation on a Vydac column, which does resolYe the be~a-carotene isomers, shows ~he beta-carotene is comprised of approximately 55% ~-cis isomer and about 45% all~trans isomer (Fig. 1 2~
~0 Elution: with hexane was continued into a different container i~media~ely after the mai.n color band, with ~wo liters ~eing collected to remoYe virt~lally all of the pale yellow material, prlmarily beta-carotene with other carotenes ~ a~d carotenoids, which was kept as a separate by-produc- of .~ 35 50 ~0% pure beta-carotene.
~:. Periodically, the column was cleansed by bac~-washing wi~h a polar solvent, typically acetone or e~hanol, ~o ' " '; ` '' `i ',` ~, '., ' ! 'j '.
,7 ~ 2~ ~ ~
~; WO94/10140 PCT/US93/10314 ~-.; ;,; .
remove oxy~genated carotenoids, plant neutral liptds and chlorophyll from the top of the column. This material may contain small amounts of astaxanthiin and/or can~haxanthin which are valuable in fish feed a~ colorants for armed salmon ~i~ 5 and.trout. The column was wa5hed as be~ore Wi~l 40S
etha~ol/hexane solvent and pure hexane to restore it for ,~ further carotene purification. Periodically, as needed by the ~ build up of chlorophyll and other lipids which could not be : eluted as above, the top 2 n_3 n of the column was re-pac~ed with fresh alumina.
The resulting preparation of high purity betao c~rotene was evaporated to remove solven~ and yielded ~bout 95% beta carotene and 5% alpha-car~tene, as shown in Fig. 1.
Purity w~s confir~ed by thin layer chromatography and ~PLC.
!i i ~ii EXAMPL~ I~
7'~ ~O ~roduc~ion oP ~i~h ~yiritY ~ Carotene :j, , .
. This Example describes the production o~ beta-~ carotene enri ::heid in the . 9-cis iso~er fro~ the high purityi)~ beta-caxotene prepared as described ln Example I.
2 ~ Hi~h purity beta-carotene fro~ Example I was dissolved in a min~t~l amount of warm ~abs:~ut 40 50 ~C~ hexane ~,'! t:o achieve sa'curatic~n. The solution wast then chill~d, typically to ab~ut -20 C, which caused the preferential c~ tailization~of the trans-isomer of beta-carotene. 5~e .!,' 3 0 crystals were theri separated from the supernatant ss:llution by ~'?' ~iltrat:ion throu~h a hydrophobic 0. 22 ~ nyloll mem~rane filter (Micron Separations , Inc ., Ca~ridge , HA) . C~romatograD~s of `~ representatlve preparations of the supernatant enric:hed in lthe s-c s isomer (approximately 75-80S 9-cis and 15-20~ all-trans) and OL' the crystals containing ~he all-~ isom~r ~t,'~ tapproximately 80-859c all-trans and 10-15S 9~ i5) are shown in Figs. 2B and 2C, respectively.
j~ .
~ 't WO 94/tO140 ~ l 4 7 ~ PCr/US93110314 The supernat~nt solution was then evaporated to dryness under vacuum, at abaut 40 C and under low light (as .
with all Ol' the purification steps described herein) to remove the heacane, leaving a carotene preparation which was ;~ 5 substantially enriched in t~e. 9-~is isomer. Typical yield of ; the 9-cis isomer from these preparations was approximately 2-3 grams. Experience with these purification p~ocedures indicate they can readily be scaled up to pilot and production levels.
EXAMPLE I~I
apsule_Formulation ; -This Example describes ~ormulation of a dietary compcsition containing beta-carotene of the invention which is intended for oral aclministration in capsule fo~.
Ing~edient~
Hi~h Purity Beta-Carotene 3 0 mgs Vitamin E 400 I~.
Vitamin C S~o ~s The above ing~re`dients are coml:~ined and pl~ced into a gelatin capsule suitab}e for administration to humans.
.' ' ~;
. . i.
It is e~ident from the above that the subject invention provides hiqh-purity natural beta-carotene and 9-cis ~,~
beta-caro~ene which find use as dietary supple~n~nts for humans .. ¦ and other animals, an~ in the t~erapy of a number of diseases, 7.":
including cartain neoplasias, and in the prevention of other diseases, such as cardiovasc:~llar disease. FurtherTQore, t~
' in~rention pro~,rides economical meth~ds: to prepare the high-purity natural beta-carotene and 9-cis be~a-carotene from plant ma~ter, conveniently from large scale alga propagation.
rXI
~' `1 ~3 ~ ,VO94/10140 ~ 1~ 7 8 2 ~ PCT/VS93/10314 ~0 All publications and patents mentioned ln this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent5 are herein incorporated by reference to the same extent as if each individual publication or patent wa~ specifically and indiYidually indicated ~o be incorporated herein by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of' clarity of understanding, it will be ok,vious that certain changes and mc,difications ~ay be practlced within the scope of the appended claims.
,.
~-.
. ` .
~;
..
~' . ! . ` i ~ !
~ : ~
.~.'~ '.
.
. . .
';J
.. ,.:
,~ ~
:
Claims (26)
1. A method for purifying beta-carotene from plants, which comprises:
extracting the plant with a solvent to produce a crude mixture of carotenes in the extract;
removing the solvent from the extract and resuspending the extract in a non-polar solvent;
chromatographing the extract on a column of deactivated alumina; and collecting fractions from the column which contain the purified beta-carotene.
extracting the plant with a solvent to produce a crude mixture of carotenes in the extract;
removing the solvent from the extract and resuspending the extract in a non-polar solvent;
chromatographing the extract on a column of deactivated alumina; and collecting fractions from the column which contain the purified beta-carotene.
2. The method according to claim 1, wherein the plant is an alga.
3. The method according to claim 2, wherein the alga is a Dunaliella species.
4. The method according to claim 1, wherein the extraction solvent is an organic solvent.
5. The method according to claim 4, wherein the extracting organic solvent is selected from hexanes, pentanes, heptanes, octanes, petroleum ethers, cyclohexane, ethyl acetate, ethanol and mixtures thereof.
6. The method according to claim 1, wherein the non-polar solvent is a pentane, hexane, heptane, octane, or petroleum ether,
7. The method according to claim 1, wherein the alumina is deactivated with aqueous ethanol.
8. A composition prepared according to the method of claim 1 which comprises substantially purified naturally occurring beta-carotene isomers, in relative amounts of at least 40% 9-cis beta-carotene and less than about 50% all-trans beta-carotene, and substantially free of organic solvent.
9. The method according to claim 1, further comprising the steps of:
dissolving the purified beta-carotene in a non-polar solvent at about 35-60°C to form a saturated solution;
chilling the solution to about 0°C to -25°C to crystallize all-trans beta-carotene and separating the solution from the crystallized all-trans beta-carotene; and removing the solvent from the solution to yield a preparation enriched in 9-cis beta-carotene.
dissolving the purified beta-carotene in a non-polar solvent at about 35-60°C to form a saturated solution;
chilling the solution to about 0°C to -25°C to crystallize all-trans beta-carotene and separating the solution from the crystallized all-trans beta-carotene; and removing the solvent from the solution to yield a preparation enriched in 9-cis beta-carotene.
10. The method according to claim 9, wherein the purified beta-carotene is dissolved in hexane.
11. The method according to claim 9, wherein the crystallized all-trans beta-carotene is separated from the solution by filtration, centrifugation or decanting.
12. A composition produced by the method of claim 9, which comprises substantially purified naturally occurring beta-carotene isomers including at least 75% 9-cis beta-carotene, and is substantially free of organic solvent.
13. The method according to claim 9, further comprising repeating with the preparation enriched in 9-cis beta-carotene, the steps of dissolving in non-polar solvent at about 35-60°C;
chilling the solution to crystallize the all-trans beta-carotene and separating the solution from the crystals;
and removing the solvent to yield a preparation further enriched in 9-cis beta-carotene.
chilling the solution to crystallize the all-trans beta-carotene and separating the solution from the crystals;
and removing the solvent to yield a preparation further enriched in 9-cis beta-carotene.
14. A composition produced by the method of claim 13, which comprises substantially purified naturally occurring beta-carotene isomers including at least 75% 9-cis beta-carotene, and is substantially free of organic solvent.
15. A composition which comprises substantially purified naturally occurring beta-carotene isomer , in relative amounts of at least 40% 9-cis beta-carotene and less than about 50% all-trans beta-carotene, and substantially free of organic solvent.
16 4 The composition according to claim 15, formulated as a tablet, capsule or microbeadlet or oil for use as a dietary supplement.
17. The composition according to claim 15, further comprising less than 10% alpha-carotene.
18. The composition according to claim 17, further comprising 2% or less of carotenoids other than alpha- and beta-carotene and 5% or less of other cis beta-carotene isomers.
19. The composition according to claim 15, comprising at least about 60% 9-cis beta-carotene and less than 25% all-trans beta-carotene.
20. The composition according to claim 19, further comprising a pharmaceutically acceptable carrier.
21. The composition according to claim 19, formulated as a tablet, capsule or microbeadlet or oil for use as a dietary supplement.
22. The composition according to claim 19, comprising 75% or more 9-cis beta-carotene.
23. The composition according to claim 22, further comprising a pharmaceutically acceptable carrier.
24. The composition according to claim 22, formulated as a tablet, capsule or microbeadlet or oil for use as a dietary supplement.
25. A method for inhibiting a tumor in a host, which comprises administering to the host a tumor-inhibiting amount of a pharmaceutical composition which comprises substantially purified naturally occurring beta-carotene isomers, in relative amounts of at least 40% 9-cis beta-carotene and less than about 50% all-trans beta-carotene.
26. The method of claim 25, wherein the pharmaceutical composition administered to the host comprises at least about 75% 9-cis beta-carotene.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/967,897 | 1992-10-27 | ||
| US07/967,897 US5310554A (en) | 1992-10-27 | 1992-10-27 | High purity beta-carotene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2147825A1 true CA2147825A1 (en) | 1994-05-11 |
Family
ID=25513473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002147825A Abandoned CA2147825A1 (en) | 1992-10-27 | 1993-10-27 | High purity beta-carotene |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5310554A (en) |
| EP (1) | EP0666845B1 (en) |
| JP (1) | JPH09500864A (en) |
| AT (1) | ATE194830T1 (en) |
| AU (1) | AU681868B2 (en) |
| CA (1) | CA2147825A1 (en) |
| DE (1) | DE69329070D1 (en) |
| WO (1) | WO1994010140A1 (en) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU660630B2 (en) * | 1990-10-01 | 1995-07-06 | Brigham And Women's Hospital | Beta-carotene and vitamin E therapy for inhibition of major vascular events |
| US5612485A (en) * | 1992-06-04 | 1997-03-18 | Betatene Ltd Of Cheltenham | High cis beta-carotene composition |
| JPH07242621A (en) * | 1994-03-02 | 1995-09-19 | Nippon Oil Co Ltd | Method for extracting carotenoid compound |
| US5475006A (en) * | 1994-08-10 | 1995-12-12 | National Research Council Of Canada | Extensively oxidized derivatives of carotenoids, retinoids and related conjugated polyenes useful as non-toxic cell-differentiation inducers, anti-proliferative agents, and anti-tumor agents |
| US7132458B2 (en) | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| DE4429506B4 (en) * | 1994-08-19 | 2007-09-13 | Degussa Gmbh | Process for the extraction of natural carotenoid dyes |
| DE19517422A1 (en) * | 1995-05-12 | 1996-11-14 | Basf Ag | Process for the production of beta-carotene preparations with a high 9 (Z) content |
| ES2238695T3 (en) * | 1995-08-14 | 2005-09-01 | Optigenex, Inc. | CAROTENOID-NICOTINAMIDE-ZINC COMPOSITIONS AND TREATMENT METHODS USING THE SAME. |
| DE19531254A1 (en) * | 1995-08-25 | 1997-02-27 | Sueddeutsche Kalkstickstoff | Process for the extraction of carotene dyes from solid natural substances |
| HUT75371A (en) * | 1995-10-09 | 1997-05-28 | Motiv Magyar Nemet Kereskedelm | Natural carotene-concentrate of vegetable material and process for producing of that |
| US6133317A (en) * | 1995-11-15 | 2000-10-17 | Hart; Francis J. | Oxalic acid or oxalate composition and method of treatment |
| US6133318A (en) | 1995-11-15 | 2000-10-17 | Hart; Francis J. | Oxalic acid or oxalate compositions and methods for bacterial, viral, and other diseases or conditions |
| US5576349A (en) * | 1995-11-30 | 1996-11-19 | The General Hospital Corporation | Retionoic acid treatment of cardiac arrhythmia |
| IL119224A (en) * | 1996-09-09 | 2002-11-10 | Hadasit Med Res Service | Medicament for protection from effects of irradiation |
| DE19638004A1 (en) * | 1996-09-18 | 1998-03-19 | Sueddeutsche Kalkstickstoff | Recovery of beta-carotene with high trans isomer content |
| US6000551A (en) * | 1996-12-20 | 1999-12-14 | Eastman Chemical Company | Method for rupturing microalgae cells |
| US5951875A (en) * | 1996-12-20 | 1999-09-14 | Eastman Chemical Company | Adsorptive bubble separation methods and systems for dewatering suspensions of microalgae and extracting components therefrom |
| US5910254A (en) * | 1996-12-20 | 1999-06-08 | Eastman Chemical Company | Method for dewatering microalgae with a bubble column |
| US5776349A (en) * | 1996-12-20 | 1998-07-07 | Eastman Chemical Company | Method for dewatering microalgae with a jameson cell |
| US20020082459A1 (en) * | 1997-05-28 | 2002-06-27 | Bailey David T. | High purity beta-carotene and process for obtaining same |
| JPH11187894A (en) * | 1997-12-26 | 1999-07-13 | Oyo Seikagaku Kenkyusho | Composition containing highly pure 9-cis-beta-carotene and its production |
| US6309677B1 (en) * | 1998-03-24 | 2001-10-30 | Amway Corporation | Multi-carotenoid product |
| IL126076A (en) | 1998-09-04 | 2005-05-17 | Ibr Ltd | Transparent composition comprising phytoene and phytofluene |
| FR2782921B1 (en) * | 1998-09-09 | 2002-09-20 | Dior Christian Parfums | LIPID EXTRACT OF SKELETONEMA ALGAE, PROCESS OF PREPARATION AND USE IN COSMETIC AND PHARMACEUTICAL AREAS, ESPECIALLY DERMATOLOGICAL |
| US6660320B1 (en) * | 1999-06-25 | 2003-12-09 | University Of Saskatchewan Technologies Inc. | Process for producing an antioxidant extract from the bearberry plant |
| GB2358862B (en) * | 1999-12-21 | 2004-07-21 | Fermentron Ltd | Processes for Extracting Carotenoids from Biomass Carotenoid Sources |
| NZ520048A (en) * | 2000-01-27 | 2004-03-26 | Dsm N | Isolation of carotenoid crystals |
| US6852905B2 (en) | 2001-11-15 | 2005-02-08 | Paragon Trade Brands, Inc. | Fluid handling layers made from foam and absorbent articles containing same |
| EP1361280A1 (en) * | 2002-05-08 | 2003-11-12 | Wageningen University | Process for continuous production and extraction of carotenoids from natural sources |
| JP2004038515A (en) * | 2002-07-03 | 2004-02-05 | Sanyo Electric Co Ltd | Data recording device |
| US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
| US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
| US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
| US7375133B2 (en) | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
| US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
| US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
| KR20050069975A (en) * | 2002-07-29 | 2005-07-05 | 하와이 바이오테크, 인코포레이티드 | Structural carotenoid analogs for the inhibition and amelioration of disease |
| US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
| US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
| US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
| US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
| US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
| US7521584B2 (en) * | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
| US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
| US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
| US20040126338A1 (en) * | 2002-12-30 | 2004-07-01 | Rod Ausich | Process of converting trans-lutein into cis-lutein and the uses thereof |
| US7074990B2 (en) * | 2003-06-27 | 2006-07-11 | Agricultural Research Organization, The Volcani Center | Carotenoids rich paprika cultivars |
| JP4526244B2 (en) | 2003-06-30 | 2010-08-18 | ブラザー工業株式会社 | Ink jet head, ink jet printer, and method of manufacturing ink jet head |
| WO2005075575A1 (en) * | 2004-02-10 | 2005-08-18 | Nestec S.A. | Compositions containing cis-isomers of a carotenoid compound and process |
| US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
| CA2564066A1 (en) * | 2004-04-14 | 2005-11-03 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
| SG155959A1 (en) | 2004-09-28 | 2009-10-29 | Chemaphor Inc | Compositions and methods for promoting weight gain and feed conversion |
| US20060088905A1 (en) * | 2004-10-01 | 2006-04-27 | Lockwood Samuel F | Methods for the synthesis of zeazanthin |
| CA2602183C (en) | 2005-03-18 | 2014-05-06 | Microbia, Inc. | Production of carotenoids in oleaginous yeast and fungi |
| ES2560666T3 (en) * | 2006-08-08 | 2016-02-22 | Nestec S.A. | Stable and bioavailable compositions containing carotenoid isomers for skin and hair |
| US8691555B2 (en) | 2006-09-28 | 2014-04-08 | Dsm Ip Assests B.V. | Production of carotenoids in oleaginous yeast and fungi |
| DK2214656T3 (en) * | 2007-10-26 | 2019-03-25 | Avivagen Inc | COMPOSITIONS AND PROCEDURES TO ENHANCE IMMUNE RESPONSE |
| JP5733592B2 (en) * | 2008-10-20 | 2015-06-10 | 株式会社日健総本社 | Side-effect prevention substances for dyslipidemia drugs |
| US20100166677A1 (en) | 2008-12-30 | 2010-07-01 | Avon Products, Inc. | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof |
| ES2813909T3 (en) | 2009-04-30 | 2021-03-25 | Avivagen Inc | Methods and compositions to improve the health of animals |
| US20110165662A1 (en) * | 2009-07-13 | 2011-07-07 | Inventure Chemical, Inc. | Method for harvesting microalgae suspended in an aqueous solution using a hydrophobic chemical |
| WO2011019668A1 (en) * | 2009-08-09 | 2011-02-17 | Meltology, Llc | Topical cosmeceutical formulation and methods of making and using same |
| US8771758B2 (en) * | 2010-06-30 | 2014-07-08 | Avon Products, Inc. | Use of Tiliacora triandra in cosmetics and compositions thereof |
| WO2016076454A1 (en) * | 2014-11-10 | 2016-05-19 | 한국생명공학연구원 | Method for culturing microorganisms and method for separating and purifying 9-cis β-carotene from cultured microorganisms |
| CN106278978A (en) * | 2016-08-09 | 2017-01-04 | 嘉必优生物技术（武汉）股份有限公司 | The method preparing bata-carotene crystal |
| CN106278977A (en) * | 2016-08-09 | 2017-01-04 | 嘉必优生物技术（武汉）股份有限公司 | The method preparing bata-carotene crystal |
| CN116268424A (en) * | 2016-11-17 | 2023-06-23 | 德布勒森大学 | Precursor compounds of retinoids providing vitamin A5 pathway and uses thereof |
| CN109503448B (en) * | 2018-12-28 | 2021-02-26 | 晨光生物科技集团股份有限公司 | Industrial method for extracting and preparing high-content beta-carotene from dunaliella salina |
| WO2021191929A1 (en) * | 2020-03-24 | 2021-09-30 | Chitra Vasant Savangikar | Oil rich in beta-carotene |
| GB202114072D0 (en) * | 2021-10-01 | 2021-11-17 | Givaudan Sa | Method |
| CN114890929B (en) * | 2022-04-11 | 2024-02-02 | 万华化学集团股份有限公司 | Method for dephosphorization and purification of beta-carotene solid |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3039877A (en) * | 1961-03-02 | 1962-06-19 | Nopco Chem Co | Stabilized carotene compositions |
| US3492202A (en) * | 1967-12-12 | 1970-01-27 | Pfizer & Co C | Process for the production of beta-carotene |
| US4199895A (en) * | 1977-05-25 | 1980-04-29 | Yeda Research And Development Co. Ltd. | Production of glycerol, carotenes and algae meal |
| EP0052777A1 (en) * | 1980-11-20 | 1982-06-02 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Process for the extraction of beta-carotene from algae |
| US4713398A (en) * | 1985-08-30 | 1987-12-15 | Microbio Resources, Inc. | Naturally-derived carotene/oil composition |
| US4680314A (en) * | 1985-08-30 | 1987-07-14 | Microbio Resources, Inc. | Process for producing a naturally-derived carotene/oil composition by direct extraction from algae |
| US4851339A (en) * | 1986-04-01 | 1989-07-25 | Hills Christopher B | Extraction of anti-mutagenic pigments from algae and vegetables |
| US5019668A (en) * | 1988-06-14 | 1991-05-28 | Palm Oil Research & Development Board | Recovery of carotenoids |
| JPH02117655A (en) * | 1988-10-26 | 1990-05-02 | Nishi Nippon Jiyoukasou Kanri Center:Kk | Water hyacinth carotene |
| US5206025A (en) * | 1989-05-24 | 1993-04-27 | Rhone-Poulenc Sante | Porous pharmaceutical form and its preparation |
| AU2899092A (en) * | 1990-05-18 | 1994-05-09 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| AU664104B2 (en) * | 1992-06-04 | 1995-11-02 | Cognis Australia Pty Ltd | High CIS beta-carotene composition |
-
1992
- 1992-10-27 US US07/967,897 patent/US5310554A/en not_active Expired - Fee Related
-
1993
- 1993-10-27 JP JP6511290A patent/JPH09500864A/en active Pending
- 1993-10-27 DE DE69329070T patent/DE69329070D1/en not_active Expired - Lifetime
- 1993-10-27 EP EP93925084A patent/EP0666845B1/en not_active Expired - Lifetime
- 1993-10-27 CA CA002147825A patent/CA2147825A1/en not_active Abandoned
- 1993-10-27 AT AT93925084T patent/ATE194830T1/en not_active IP Right Cessation
- 1993-10-27 WO PCT/US1993/010314 patent/WO1994010140A1/en active IP Right Grant
- 1993-10-27 AU AU54530/94A patent/AU681868B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0666845B1 (en) | 2000-07-19 |
| ATE194830T1 (en) | 2000-08-15 |
| EP0666845A1 (en) | 1995-08-16 |
| JPH09500864A (en) | 1997-01-28 |
| AU5453094A (en) | 1994-05-24 |
| WO1994010140A1 (en) | 1994-05-11 |
| AU681868B2 (en) | 1997-09-11 |
| DE69329070D1 (en) | 2000-08-24 |
| US5310554A (en) | 1994-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2147825A1 (en) | High purity beta-carotene | |
| US7253294B2 (en) | Isolation of lutein from alfalfa | |
| EP0356499B1 (en) | Pigmentation supplements for animal feed compositions | |
| JP5721740B2 (en) | Combination of carotenoids and epilutein | |
| WO2009051470A1 (en) | Flavour enhancers/food seasoning from seaweeds and a method for producing and uses thereof | |
| US8034983B2 (en) | Process for the preparation of xanthophyll crystals | |
| US7351424B2 (en) | Enhanced purity trans-lutein-ester compositions and methods of making same | |
| TWI239245B (en) | Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention | |
| WO2006037725A1 (en) | Formulation for oral administration having a health-promoting effect on the cardiovascular system | |
| RU2469732C1 (en) | Method of obtaining carotinoid complex from starfish | |
| JP2009007346A (en) | Prophylactic for diabetes-combined disease | |
| WO2008023283A2 (en) | Stabilized esters of lutein | |
| CN111264861A (en) | Microcapsule of natural astaxanthin and preparation method thereof | |
| Khandual | Microbial source of astaxanthin: Its use as a functional food and therapeutic agent | |
| WO2005034975A1 (en) | Plant seed extract composition and process for producing the same | |
| KR101924734B1 (en) | Extraction method of lutein from Zostera marina | |
| US20040176475A1 (en) | Isolation of lutein from alfalfa | |
| JP2006022033A (en) | Neovascularization inhibitor | |
| JPH10212228A (en) | Carcinogenesis or neoplasm metastasis inhibitor | |
| CN1415309A (en) | Nano selenium of Melatonin and its preparation method | |
| KR102644597B1 (en) | Antioxidative composition having improved stability | |
| Wibowo | Prospects and health promoting effects of brown algal-derived natural pigments | |
| Lee | Astaxanthin: Sources, Properties and Benefits | |
| Qadir et al. | Lutein and zeaxanthin | |
| RU2456336C1 (en) | Eifitol fish oil production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |